

ANCILE.037A

PATENT



**COMPOSITION FOR IMPROVING SLEEP QUALITY AND EFFICIENCY, AND
METHODS OF PREPARING AND USING THE COMPOSITION**

Related Applications

[0001] This application ^{is a continuation-in-part of and} claims priority from U.S. Patent Application Ser. No. 09/358,375, PROCESS FOR THE EXTRACTION OF VALERIAN ROOT, filed July 21, 1999, by Andrews *et al.*; U.S. Patent Application Ser. No. 09/620,801, ^{now U.S. 6,383,526} PROCESS FOR THE EXTRACTION OF VALERIAN ROOT, filed July 21, 2000, by Andrews *et al.*; and U.S. Patent Application Ser. No. 60/264,872, COMPOSITION FOR IMPROVING SLEEP QUALITY AND EFFICIENCY, AND METHODS OF PREPARING AND USING THE COMPOSITION, by Andrews *et al.*, filed January 29, 2001, the entire disclosures of which are each incorporated by reference herein.

Background of the Invention

Field of the Invention

[0002] The present invention relates to a pharmaceutical composition for improving sleep quality, and more specifically relates to a pharmaceutical composition comprising pharmaceutically effective amounts of an extract of the plant *Valeriana officinalis* L. (*V. officinalis* L) and methods of using such compositions to improve sleep quality, as measured via a variety of specific criteria.

Description of the Related Art

[0003] Extracts of the root of the plant *Valeriana officinalis* L. (*V. officinalis* L) have been used for medicinal purposes for over a century. Certain valerian extracts, including aqueous extracts, are known to have sedative and anxiolytic effects, but the active components have not been clearly and positively identified. [Leathwood P.D., Chauffard F., Heck E., and Munoz-Box R. Aqueous extract of valerian root (*Valeriana officinalis* L.) improves sleep quality in man. *Pharmacology, Biochemistry and Behavior*, 17:65-71, 1982; Leathwood P.D. and Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. *Planta Medica*, 2:144-148 (1985)] Such effects are described, for example, by


Balandrin *et al.* in U.S. Patent 5,506,268, which is incorporated by reference herein in its entirety. Presently, valerian extracts are available as dietary supplements; these dietary supplements primarily comprise dried root or extracts from the root, formulated into tablets or soft gelatin capsules. Each dose contains between approximately 50 mg and approximately 1 gram of dried root or extract. The use of these dietary supplements is extensive, with an estimated 210 million doses sold annually in the United States and 125 million doses sold annually in Europe. *See* Grunwald, J., "The European Phytomedicines Market - Figures, Trends Analyses" *Herbal Gram*, 1995.

[0004] *V. officinalis* L. is a member of the Valerianaceae family. This plant grows from a short rhizome to approximately 2 meters in height, it flowers, and then dies back again in the winter. *Valeriana officinalis* L. has pinnately-divided leaves, typically with six to ten pairs of lance-shaped leaflets, and bears many small white or pink flowers in a dense head of several stalked clusters. These heads bare small (5 millimeters) tapered seeds.

[0005] It is not fully understood which constituents of *Valeriana officinalis* L., and/or of the other heretofore unidentified members of the Valerianaceae family, are responsible for the sedative and/or anxiolytic action of valerian extracts. Nonetheless, the valepotriates (iridoids) as well as valerenic acid, a sesquiterpenoid compound, and the derivatives of valerenic acid (for example, acetoxyvalerenic acid and hydroxyvalerenic acid) along with kessane derivatives, valerenone, valerenal, and certain amino acids are present in valerian extracts. Of these components, the valepotriates and valerenic acids are generally considered to contribute to the sedative action of valerian extracts, but have not been clearly and positively identified as such. *See* Hendriks H. *et al.* "Pharmacological Screening of valerenal and some other components of essential oil of *Valeriana officinalis*" *Planta Medica* 42, 62-68 (1981); Bos R. *et al.*, "Analytical aspects of phytotherapeutic valerian." (1996); Houghton P.J., Valerian. The Genus *Valeriana*. Harwood Academic Publishers, London (1997).

[0006] Valepotriates (iridoids) are triesters of polyalcohols with an iridoid structure. They are unstable, thermolabile compounds that decompose in alcoholic solutions and under acidic or alkaline conditions. *See* Bos R. *et al.* Analytical aspects of Phytotherapeutic Valerian preparation, 1996; 7:143-151. The major decomposition products

of diene type valepotriates are baldrinals, including: baldrinal (from the valepotriates valtrate and acevaltrate) and homobaldrinal (from the valepotriate isovaltrate). Relative to the above-described valepotriates, valerenic acid and its derivatives (for example, acetoxyvalerenic acid and hydroxyvalerenic acid) are chemically stable. While valepotriates and valepotriate decomposition products or derivatives are found in many species of Valerianaceae, *Valeriana officinalis* L. is the only species that has been identified as possessing extractable valerenic acid in its roots. The structures of valerenic acids and certain valepotriates and valepotriate decomposition products are presented below.



[0007] Several processes are known for the extraction of valerian roots, but none of these known processes simultaneously retains valerenic acid, maximizes the content of the valerenic acids (e.g., of valerenic acid and of the valerenic acid derivatives), and minimizes the content of valepotriates. Indeed, certain of these extraction processes were designed to retain or maximize the yield of valepotriates. For example, Broese *et al.*, CH 000046778

(1978), describe obtaining a stable extract of a valerian preparation in which the essential valepotriates are present undiminished in the resultant extract, and Wischniewski *et al.*, U.S. Patent 4,313,930 (1982), describe the production of a stable valepotriate composition, through the use of a pharmaceutically acceptable sheathing material, from a pharmaceutically active Valerianacea extract. Other known extraction processes focus on removing the odors associated with the valepotriate and valepotriate derivatives, but do not maximize the content of valerenic acid and the valerenic acid derivatives.

[0008] For example, Cerise *et al.*, U.S. Patent 5,211,948 (1993), describe extracting Valerian roots with water over a period of 2 to 5 hours at a temperature from 65 to 75°C. This water-based extraction is described as leading “to degradation of the valepotriates while preserving the valerenic acids of the valerian roots.” The ‘948 patent also states that extraction of valerian roots with hot water (2 to 5 hrs at 65 – 75°C), preferably three successive times, leads to degradation of the valepotriates while “preserving” the valerenic acids. However, the results of the current examples, *see esp.* Examples 6-10, indicate that the valerenic acids are “preserved” in the roots and are not extracted.

[0009] Valerenic acid is a chemically stable compound that is used as an identification test for *V. officinalis* in the United States Pharmacopoeia (USP23-NF18, Supplement 8). Thus, to develop a valerian based sedative product, it would be beneficial to enrich valerenic acids in the extract or substantially retain valerenic acid from the root. Due to poor solubility of valerenic acids in water, the process of the ‘948 Patent is inefficient in extracting these compounds. The extraction process of the present invention, on the other hand, efficiently enriches valerenic acids. In this respect, the present invention is far more superior than the Cerise process.

[0010] Other extraction processes are known, but are conducted in the presence of unusual, expensive, or otherwise undesirable solvents and/or at unusual or undesirable conditions, such as low pH. For example, Thies *et al.*, U.S. Patent 3,422,090 (1969) describe extracting roots and rhizomes of plants of the genus Valeriana at a temperature below 30°C with a lipophilic solvent in the presence of an aliphatic carboxylic acid, specifically glacial acetic acid, within a pH range of about 3 to about 7. Gehrlicher, DE 03112737 (March 31, 1981) (“the ‘737 application”) describes obtaining epoxide-free sedative agents from plants

of the Valerianaceae family by extracting at elevated temperatures in the presence of weak acids and catalytic amounts of strong acids at pH < 3, with either lower aliphatic alcohols or mixtures of lower aliphatic alcohols with water or anhydrous non-polar solvents. The process of the '737 application, however, retains baldrinals and other valepotriate decomposition products in the extract.

Summary of the Invention

[0011] A pharmaceutical composition comprising extracts of the root of a plant of the family Valerianaceae, and methods of using such composition and/or extracts of the root of a plant of the family Valerianaceae to improve sleep quality and sleep efficiency and to improve sleep structure and sleep architecture, are described. Sleep quality, sleep efficiency, sleep structure and sleep architecture may be in the context of various criteria or parameters, as described herein.

[0012] Specifically, a pharmaceutical composition that reduces wake after sleep onset, increases total sleep time, increases sleep efficiency, and/or increases sleep time spent in sleep stages three and four, in a normal adult is described, the composition comprising therapeutically effective amounts of valerenic acid and its derivatives, kessane derivatives, valeranone, valerenal, and amino acids. The composition may be prepared by the steps of (i) adding the roots to an alcoholic extraction solvent to form a mixture, wherein the alcoholic extraction solvent comprises between approximately 50% (v/v) to approximately 100% (v/v) ethanol in a remainder of water, and (ii) heating the mixture to a temperature of between approximately 70°C to approximately 80°C for a period of at least two hours; wherein valerenic acid is present in the extract, the content of valepotriates in the extract is substantially reduced with respect to its content in the root, and the content of valerenic acids in the extract is not substantially reduced with respect to its content in the root; and minimizing the yield of unstable valepotriates. The valerenic acid derivative, where present, is preferably selected from acetoxyvalerenic acid, hydroxyvalerenic acid, valerenal, valerenol. The therapeutically effective amount of valerenic acid, where present, is preferably between about 0.15 mg and about 15 mg, or between about 0.3 mg and about 15 mg. The therapeutically effective amount of acetoxyvalerenic acid, where present, is preferably between about 0.185 mg and about 18.5 mg, or between about 0.37 mg and about

18.5 mg; the therapeutically effective amount of hydroxyvalerenic acid, where present, is preferably between about 0.005 mg and about 0.5 mg, or between about 0.01 mg and about 0.05 mg; the therapeutically effective amount of valerenal, where present, is preferably between about 0.115 mg and about 0.46 mg; the therapeutically effective amount of valerenol, where present, is preferably between about 0.0025 mg and about 0.01 mg.

[0013] Also disclosed are methods of reducing the number of wakings after sleep onset and/or the length of wakings after sleep onset in a patient. These methods may comprise administering a pharmaceutically-active extract of the root of a plant of the family Valerianaceae to the patient; administering the extract in a single dosage between about 50 mg and about 5000 mg; delivering the dosage to the patient between approximately one-half and approximately two hour before bedtime; and delivered the dosage for at least two consecutive nights. Preferably, the dosage is delivered at about one hour before bedtime, and more preferably at between about one half and one and one-half hour before bedtime.

[0014] Also disclosed are methods of reducing the number of wakings after sleep onset and/or reducing the length of wakings after sleep onset in a patient. These methods may comprise the steps of administering to the patient a pharmaceutically-active extract of the root of a plant of the family Valerianaceae processed by the steps of adding the roots to an alcoholic extraction solvent to form a mixture, wherein the alcoholic extraction solvent comprises between approximately 50% (v/v) to approximately 100% (v/v) ethanol in a remainder of water, and heating the mixture to a temperature of between approximately 70°C to approximately 80°C for a period of at least two hours; wherein valerenic acid is present in the extract, the content of valepotriates in the extract is substantially reduced with respect to its content in the root, and the content of valerenic acids in the extract is not substantially reduced with respect to its content in the root, where the extract is administered in a single dosage between 50 mg and 5000 mg; and the dosage is delivered to the patient between approximately one-half and two hours before bedtime.

[0015] Also disclosed are methods for increasing total sleep time and/or increasing sleep efficiency and/or increasing sleep time spent in sleep stages three and four comprising administering a pharmaceutically-active extract of the root of a plant of the family Valerianaceae to a patient, administering the extract in a single dosage between 50 mg and

5000 mg, delivering the dosage to the patient approximately one-half and two hour before bedtime; and delivering the dosage for at least two consecutive nights. Alternative methods of increasing total sleep time and/or increasing sleep efficiency are disclosed that comprise the steps of administering to a patient a pharmaceutically-active extract of the root of a plant of the family Valerianaceae processed by adding the roots to an alcoholic extraction solvent to form a mixture, wherein the alcoholic extraction solvent comprises between approximately 50% (v/v) to approximately 100% (v/v) ethanol in a remainder of water, and heating the mixture to a temperature of between approximately 70°C to approximately 80°C for a period of at least two hours; wherein valerenic acid is present in the extract, the content of valepotriates in the extract is substantially reduced with respect to its content in the root, and the content of valerenic acids in the extract is not substantially reduced with respect to its content in the root, administering the extract in a single dosage between 50 mg and 5000 mg, and delivering the dosage to the patient approximately one-half and two hour before bedtime. Any of the above-mentioned dosages is preferably delivered for at least three, four, five, six, seven or more consecutive nights. The pH of the above-described mixture is preferably maintained above a pH of approximately 3.0, 4.0, 5.0 or greater.

Brief Description of the Drawings

[0016] The accompanying figures and drawings are incorporated in and form part of the specification. The accompanying figures and drawings merely illustrate preferred aspects and embodiments of the invention; and are not intended to limit the scope of protection or the proprietary rights afforded by the present application, future applications claiming priority to the present application, and any patent that may issue from such applications. Together with the remainder of the specification, the accompanying figures and drawings serve to fully explain the principles of the invention to those of skill in the art. In the drawings:

[0017] Figure 1 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) sleep latency (in minutes) as measured by the change in the mean sleep latency for each treatment group over time.

[0018] Figure 2 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) sleep latency (in minutes) measured as at the

mean and 95% confidence intervals for change in sleep latency from baseline to days 8/9 for each treatment group.

[0019] Figure 3 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) sleep latency (in minutes) as measured by the change from baseline to study days 8/9 for individual patients by treatment group.

[0020] Figure 4 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) wake after sleep onset (in minutes) as measured by the change in the mean wake after sleep onset for each treatment group over time.

[0021] Figure 5 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) wake after sleep onset (in minutes) as measured by the mean and 95% confidence intervals for change in wake after sleep onset from baseline to days 8/9 for each treatment group.

[0022] Figure 6 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) wake after sleep onset (in minutes) as measured by the change from baseline to study days 8/9 for individual patients by treatment group.

[0023] Figure 7 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) total sleep time (in minutes) as measured by the change in the mean total sleep time for each treatment group over time.

[0024] Figure 8 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) total sleep time (in minutes) as measured by the mean and 95% confidence intervals for the change in total sleep time from baseline to days 8/9 for each treatment group.

[0025] Figure 9 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) total sleep time (in minutes) as measured by the change from baseline to study days 8/9 for individual patients by treatment group.

[0026] Figure 10 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) sleep efficiency (expressed as a percentage) as the change in the mean sleep efficiency for each treatment group over time.

[0027] Figure 11 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) sleep efficiency (expressed as a percentage) as measured by the mean and 95% confidence intervals for change in sleep efficiency from baseline to days 8/9 for each treatment group.


[0028] Figure 12 depicts the effect of a pharmaceutically-active extract of Valerian as described herein on PSG (polysomnography) sleep efficiency (expressed as a percentage) as measured by the change from baseline to study days 8/9 for individual patients by treatment group.

Detailed Description of the Preferred Embodiments

[0029] One objective of the present invention is to provide a process by which valerenic acid and its derivatives (e.g., acetoxyvalerenic acid and hydroxyvalerenic acid) are isolated in an extract of the roots of plants of the Valerianaceae family. More specifically, plants of the species *Valeriana officinalis* L. are used. Another objective of the present invention is to provide a process by which valepotriates (iridoids) are substantially reduced in an extract with respect to their content in the roots, and preferably are not purified and/or isolated in an extract of the above-described roots. Another objective of the present invention is to provide a relatively inexpensive process that can be performed at commercial scale for the production of an extract having valerenic acids specifically, and valerenic acid and its derivatives (for example, acetoxyvalerenic acid and hydroxyvalerenic acid) generally, from the above-described roots. Another object of the present invention is to provide an extraction process through which the extracted roots may be chemically identified as the roots of *Valeriana officinalis* L. Yet another object of the present invention is to provide a process for preparing a medicament containing an extract of the above-described roots. In the preferred embodiment of the extraction process of the present invention, but not necessarily in all embodiments of the extraction process of the present invention, these objectives are simultaneously met. Most preferably, the extraction process of the present invention significantly reduces the amount of valepotriates in the extract and the amount of valerenic acid and/or valerenic acids is unaltered in the extract when compared to known processes.

[0030] According to the present invention, at least one of these objectives is met, at least in part, through an extraction process. In conjunction with this extraction process, methods for processing the root prior to extraction, for forming a drug substance via the addition of excipient, for drying and milling the drug substance, and for formulating an ingestible entity, such as a tablet, capsule, tea, suspension, or other medicinal food, are described. These methods provide a medicament of the present invention, which contains the extract of the present invention.

[0031] Shown below is a structure of an exemplary compound isolated according to the preferred methods described herein.



[0032] wherein, for the following compounds, R and R¹ are defined as follows:

	I. R	II. R ¹
Valerenic Acid	COOH	H
Hydroxyvalerenic Acid	COOH	OH
Acetoxyvalerenic Acid	COOH	OCOCH ₃
Valerenal	CHO	H
Valerenol	CH ₂ OH	H

[0033] Extracts of *V. officinalis* L. roots exhibit sedative and anxiolytic action. Pharmacology studies indicate that *V. officinalis* exerts sedative properties apparently by a combination of central nervous system (CNS) depression and smooth muscle relaxation. *V. officinalis* has been shown to decrease mobility, potentiate barbiturate induced sleep time, alter performance on rotorod and traction tests, act as an anti-convulsant, and exert anti-spasmolytic properties. Studies in animals (mainly rodents) show that individual constituents of *V. officinalis* exert similar sedative and pharmacological properties, although they are unable to account for the total activity of the plant *See* Houghton P.J., Valerian. The Genus Valeriana. Harwood Academic Publishers, London (1997).

[0034] Studies intended to attribute the activity of plant extracts to individual constituents typically take into account the amount of one or more active compound(s) present in the plant extract and the concentration which shows activity in a test system. HPLC analysis of the extract obtained from the current process shows that the extract may contain approximately 0.0% to approximately 0.5% and preferably about 0.3% valerenic acid, approximately 0.0% to approximately 0.5% and preferably about 0.37% (or about 0.4%) acetoxyvalerenic acid, and approximately 0.0% to approximately 0.1% and preferably 0.01% hydroxyvalerenic acid, and preferably about 0.046% of valerenal and 0.001% of valerenol. In milligram dosages, these percentages would refer to an extract containing approximately 0.15 mg to approximately 15 mg of valerenic acid, and preferably about 0.3 mg to about 15 mg valerenic acid; approximately 0.185 mg (about 0.2 mg) to about 18.5 mg (about 20 mg) of acetoxyvalerenic acid, and preferably about 0.37 mg (about 0.4 mg) to about 18.5 mg (about 20 mg) of acetoxyvalerenic acid; approximately 5 μ g to about 0.5 mg hydroxyvalerenic acid, and preferably about 10 μ g and 50 μ g of hydroxyvalerenic acid; approximately 0.023 mg (about 2 μ g) to about 2 mg of valerenal; and approximately 0.5 μ g to about 50 μ g of valerenol. The therapeutically effective amount of extract is between about 50 mg and about 5000 mg, and preferably between about 100 mg and 5000 mg. Analysis of the extract by steam distillation shows that the extract may contain approximately 0.0% to approximately 5% of total volatile oils and preferably 1%, 2%, 3%, 4%, or more of total volatile oils.

[0035]

Preferred Percentage of Isolated Components

810130

Compound Name	Example of Preferred Percentage (wt/wt extract)
Valerenic Acid	0.30 ⁽¹⁾
Hydroxyvalerenic Acid	0.01 ⁽¹⁾
Acetoxyvalerenic Acid	0.37 ⁽¹⁾
Valerenal	0.046 ⁽²⁾
Valerenol	0.001 ⁽²⁾
10(14)-Aromadendren-4-ol	0.005 ⁽²⁾
6,10(14)-Guaiadien-4-ol	0.006 ⁽²⁾

⁽¹⁾ Calculated by HPLC⁽²⁾ Calculated from yield obtained during bio-assay guided fractionationSleep Quality, Sleep Efficiency, Sleep Structure and Sleep Architecture Parameters

[0036] A variety of diagnostic methods are known or may be developed to examine both specific and generalized sleep disorders. Among these methods, which include sleep diaries and logs, validated questionnaires, and wrist-worn actigraphs, polysomnography, or PSG, is generally considered a most reliable tool in the diagnosis of sleep disorders. PSG is usually performed in a dedicated sleep laboratory, and may involve the simultaneous recording of multiple physiologic parameters during sleep, including an electroencephalogram (EEG), electromyography of the submental and lower extremity musculature, measurement of eye movements, oxygen saturation, body movement, and electrocardiogram.

[0037] Based on polysomnographic measurement, mammalian sleep may be divided into a series of discrete stages. Stages 1 through 4 are generally referred to as Non-Rapid Eye Movement (NREM) Sleep. Stage 1 sleep is generally viewed as the transition between wake and sleep; Stage 2 typically follows Stage 1, and is considered baseline sleep and occupies roughly half of sleep time; Stages 3 and 4 are referred to as "slow wave" or "delta" sleep and are generally recognized to be the deepest and most restorative stages of sleep. REM (Rapid Eye Movement) Sleep is also sometimes referred to as Stage 5 and consists of an active stage of sleep with characteristic eye movement. Each of these sleep stages has a characteristic EEG pattern, and over a night, an individual will generally progress or cycle through these stages a number of times. Each 30-second unit of time over

the course of a PSG recording is generally referred to as an "epoch," and based on the EEG pattern, a sleep technologist will be able to assign a sleep stage (or awake designation) to each epoch.

[0038] In approaching primary insomnia, which may be characterized as an insomnia not known to be a result of another specific medical, psychiatric, or sleep disorder, there are a variety of parameters of a PSG study that may be examined. These parameters, of course, may also be used to evaluate non-primary insomnia, as well. As used herein, the most common and useful quantitative parameters include the following:

[0039] *Time in Bed* (TIB)- the duration, in minutes, of the entire sleep study from the beginning to the end of the PSG recording. Generally a fixed duration (480 minutes).

[0040] *Total Sleep Time* (TST)- the sum, in minutes, of all time (epochs) spent in either REM or NREM (Stages 1-4) sleep.

[0041] *Sleep Efficiency* (SE)- expressed as a percentage, the fraction of the Time in Bed that is spent asleep in REM or NREM. Derived by the calculation $TST/TIB \times 100$.

[0042] *Sleep Latency or Sleep Onset Latency* (SL/SOL)- the time in minutes from the beginning of the PSG recording until the first three epochs of Stage 1 or a single epoch or any other sleep stage (Stages 2-4, REM).

[0043] *Latency to Persistent Sleep* (LPS)- the time in minutes from the beginning of the PSG recording until 10 uninterrupted minutes of sleep epochs (any sleep stage).

[0044] *Total Wake Time* (TWT)- over the course of the entire sleep recording (or TIB), the total time in minutes of epochs spent awake (not in any sleep stage).

[0045] *Wake During Sleep*- the time, in minutes, of epochs spent awake between the onset of persistent sleep (as described by 10 consecutive minutes of sleep epochs of any stage) and the last epoch of any sleep stage.

[0046] *Wake After Sleep*- the duration, in minutes, of time awake after the last sleep epoch (any stage) until the end of the recording period.

[0047] *Wake After Sleep Onset* (WASO)- the sum of Wake During Sleep and Wake After Sleep.

[0048] *Number of Awakenings*- the number of times after onset of persistent sleep in which an awakening of greater than 30 seconds occurs. (The minimum wake duration can be defined as other than 30 seconds as well.)

[0049] The above parameters generally refer to sleep structure or the organization and duration of time spent awake or asleep. These parameters may also be subdivided into measurements of sleep onset, or induction, such as LPS and SL/SOL and sleep maintenance or continuity, such as Wake During Sleep. Other parameters, such as SE, and TST, may be considered to be mathematical mixtures of these two perspectives, as they combine information related to both rapidity of falling asleep and degree to which sleep remains uninterrupted.

[0050] In addition to sleep structure, there are also various parameters that are generally used to describe sleep architecture, in which the timing, duration, and organization of the discrete stages of sleep are often examined. Some of the more common sleep architecture parameters, as used herein, are as follows:

[0051] *Latency to Stage 2*- the time, in minutes, from the beginning of the PSG recording until the first epoch of Stage 2 sleep.

[0052] *REM Latency*- the time, in minutes, from the beginning of the PSG recording until the first epoch of REM sleep.

[0053] *Percent REM Sleep*- the amount, expressed as a percentage, of the total time spent in REM stage sleep divided by the Total Sleep Time.

[0054] *Percent Slow Wave Sleep*- the amount, expressed as a percentage, of the total time spent in either Stage 3 or Stage 4 sleep divided by the Total Sleep Time.

[0055] Many of the above sleep structure and architecture parameters, particularly ones pertaining to sleep structure, may also be determined, albeit in a less precise fashion, by sleep diaries and questionnaires as well as by actigraphy. Many morning-after sleep surveys, for example, solicit patient's perception of the time to sleep onset, number and duration of awakenings, quality of sleep, and degree of feeling refreshed in the morning.

Valerenic Acids

[0056] Valerenic acids are components of *V. officinalis* extracts and are likely responsible for the sedative activity of valerian. The valerenic acids (for example, valerenic

acid, acetoxyvalerenic acid, and hydroxyvalerenic acid) of *V. officinalis* may exert sedative properties. For example, valerenic acid administered intraperitoneally (IP) at a dose of 100 mg/kg, caused a decrease in motor activity, a decrease in respiratory rate, absence of righting reflex, ataxia, a decrease of abdominal muscle tone, and a decrease in rotarod performance in mice. See Hendrick H, Bos R, Allersma D, Malingre T, and Koster A. Pharmacological Screening of Valerenal and some other Components of Essential Oil of *Valeriana officinalis*. *Planta Medica*: 1981; 42: 62-68. In a follow up study, the same researchers showed that valerenic acid influenced performance on both the rotarod and traction tests with statistical significance obtained at 100 mg/kg, IP. Valerenic acid was also shown to potentiate pentobarbital induced sleeping time at doses of 50 and 100 mg/kg, IP. See Hendricks H, Bos R, Woerdenbag H and Koster A, Central Nervous Depressant Activity of Valerenic Acid in the Mouse. *Planta Medica*: 1985; 51: 28-31. The anti-convulsant properties of valerenic acid have been characterized, see Hiller K. and Zetler G. "Neuropharmacological studies on ethanol extracts of *Valeriana officinalis* L.: Behavioral and anticonvulsant properties" *Phytotherapy Res.* 10 (1996) 145-151; it was shown that valerenic acid antagonized picrotoxin induced convulsions at 12.5 and 25 mg/kg, IP in mice. At a concentration of 1 mmole/liter, valerenic acid and acetoxyvalerenic acid were shown to inhibit the enzyme system which catalyses breakdown of GABA in the brain by 20% and 38%, respectively. See Riedel E, Hansel R and Ehrke G. Inhibition of GABA catabolism by valerenic acid derivatives. *Planta Medica*: 1982 ; 46: 219-220. An increase in brain concentrations of GABA, a potent central nervous system (CNS) depressant, may thus lead to a decrease in CNS activity and sedation.

[0057] One aspect of the current method is useful in verifying that the particular roots to be extracted are roots of the species *V. officinalis* L. and not of another plant, or more specifically of another member of the Valerianaceae family. And because many of the plants in this family are phenotypically similar and are therefore capable of being substituted for one another, a preferable means to identify *V. officinalis* L. is to identify valerenic acid directly in the extract.

[0058] Preferred extraction processes according to the invention, unlike known methods of extracting *V. officinalis* L. roots from water, yields a measurable amount of

valerenic acid. As shown herein, *see esp.* Examples 6, 7, 8, 9, and 10, the extraction of *V. officinalis* L. roots in water yields substantially less valerenic acids than the methods described herein. As noted above, the present extraction method is therefore preferable to, and provides benefits not obtainable through the use of known water-based extraction methods. For example, the present process allows for the extraction of a pharmaceutically-effective composition that can be independently verified as being from the roots of *V. officinalis* L., rather than from the roots of another plant or of a phenotypically-similar member of the Valerianaceae family.

[0059] In another embodiment of the invention, the amount of total valerenic acids or of a specific valerenic acid may be a marker for the strength/potency of the extract. For example, 0.6% - 1.0% total valerenic acids may serve as such a marker.

Volatile Oils

[0060] Another preferred aspect of the extracts and extraction methods provided herein that is distinct from known valerian extractions and extraction methods concerns the yield of a measurable amount of volatile oil in the extract. As shown in, for example, Example 10, described in detail below, the extraction of *V. officinalis* L. roots in water does not yield isolatable volatile oil.

[0061] The volatile oils of *V. officinalis* are a very complex mixture of mostly mono- and sesquiterpenoids. Over 150 compounds have been identified in the volatile oil fraction and have been described. *See* Bos R. Analytical and Phytochemical Studies on Valerian and Valerian Based Preparations. Thesis: Offsetdrukkerij Ridderprint B.V., Ridderkerk: 1997; 13-21 and 77-93.

[0062] Several studies have reported sedative effects of the total volatile oil and/or volatile oil constituents (kessoglycol diacetate, kessoglycol 2-acetate, kessylglycol 8-acetate, valerenal, and valerenone) *in vivo* animal models of sedation. *See* Hazelhoff B, Malingre T and Meijer D. Antispasmodic effects of valeriana compounds: an *in-vivo* and *in-vitro* study on guinea-pig ileum. Arch Int Pharmacodyn Ther.: 1982; 257(2): 274-87; Hendricks, *et al.* 1981; Hikino H, Hikino Y, Kobilata H, Aizawa A, Konno C and Oh'Izumi Y. Sedative Principles of Valeriana Roots. Shoyakugaku Zasshi: 1980; 34(1): 19-24. Thus, the volatile oil may contribute to the overall sedative properties of the extract.

[0063] However, even the most abundant volatile oil is generally a minor component in the extract. Thus, individual components of the volatile oil will not typically, but may, be justified as a useful marker for monitoring the consistency of the extract across manufactured batches. In another embodiment of the invention, therefore, the amount of total volatile oils may be a marker for the strength/potency of the extract. For example, approximately 0.6% to approximately 2.2% total volatile oil may serve as such a marker.

[0064] The volatile oil content typically ranges from approximately 0.0% to approximately 5.0%, and preferably approximately 0.6 to approximately 2.2% (v/w).

[0065] In sum, the pharmacology studies cited in the literature indicate that volatile oil components of *V. officinalis* may be related to sedative activity. The current process may retain this component and the assay of the total volatile oil component, as the measurement from steam distillation indicates that the product has about 0.0 % to about 5% of volatile oil. The current method thus may provide a way of control for the total amount of volatile oil within the extract. Accordingly, the present extraction method is preferable to, and provides benefits not obtainable through, the use of known water-based extraction methods.

Valepotriates And Valepotriate Decomposition Products

[0066] Another aspect of the current method that is distinct from known valerian extraction method concerns the in-process reduction of the content of valepotriates in the extracts. Valepotriates are triesters of polyalcohols with an iridoid structure and an epoxy group that have reported cytotoxic and mutagenic properties. Valepotriates are divided into two main groups: diene type (which include valtrate, isovaltrate, and acevaltrate) and monoene type (which include didrovaltrate and isovaleroxyhydroxydicrovaltrate (IVHD). Valepotriates are thermolabile and decompose under acidic, alkaline, or alcoholic conditions. See Bos, 1996. Shown below are chemical structures of certain valepotriates.

Diene Valepotriates

	R₁	R₂	R₃
Valtrate	COCH ₂ CH(CH ₃) ₂	COCH ₂ CH(CH ₃) ₂	COCH ₃
Isovaltrate	COCH ₂ CH(CH ₃) ₂	COCH ₃	COCH ₂ CH(CH ₃) ₂
1-α-Acevaltrate	COCH ₂ C(CH ₃) ₂ OCOCH ₃	COCH ₂ CH(CH ₃) ₂	COCH ₃

Monoene Valepotriates

	R₁	R₂	R₃	R₄
Didrovaltrate	COCH ₂ CH(CH ₃) ₂	COCH ₃	COCH ₂ CH(CH ₃) ₂	H
IVHD valtrate	COCH ₂ CH(CH ₃) ₂	COCH ₃	COCH(OCOCH ₂ CH(CH ₃) ₂)CH(CH ₃) ₂	OH

[0067] While valepotriates may contribute to the pharmaceutical activity of valerian extracts, valepotriates and their decomposition products are also potentially dangerous. For example, valepotriates have been shown to be cytotoxic *in vitro*, and exhibit potential mutagenic activity. *See* Von der Hude W., Scheutwinkel-Reich M., Braun R., and Dittmar W. "In vitro mutagenicity of valepotriates" *Arch Toxicol* 56 (1985) 267-71; Von der Hude W., Scheutwinkel-Reich M., and Braun R. "Bacterial mutagenicity of the tranquilizing constituents of Valerianaceae roots." *Mutat Res* 169 (1986) 23-7). Also, orally-administered valepotriates reach the brain and other organs *in vivo*, and have been shown to be capable of irreversibly alkylating DNA and proteins (Wagner, H. and Jurcic, K, *Planta Med.* (1980) 38:366-376). As cytotoxic and mutagenic effects have been reported for the valepotriates the present invention provides a method of control for the levels of this class of compounds. This process comprises adding the ground roots to an alcoholic extraction solvent and heating to a temperature between 70°C and 80°C for a period of at least three hours. By this process the extract contains valerenic acids but has levels of valepotriates that are substantially reduced compared to the content of valepotriates that occur naturally in the roots of the plant.

[0068] Valepotriates are not unique to the genus *officinalis*, but are known constituents of most *Valeriana* species. *V. officinalis* mainly contains valepotriates of the diene type (valtrate, isovaltrate, and some acevaltrate), whereas both *V. wallichii* and *V. edulis* also contain considerable amounts of the monoene type (didrovaltrate and isovaleroxyhydroxydidrovaltrate). *See* Houghton, 1997. A few studies explored the content

of different valepotriates in *V. officinalis* root. The studies indicate that only the diene valepotriates, valtrate, and isovaltrate are present in significant amounts, and all other valepotriates are present in trace amounts (see Table 1, below).

Table 1.
Content of Valepotriates in Dried *V. officinalis* Roots

1000

Valepotriate	Content in dried root (%)	Reference
Valtrate	0.095 – 0.95	Granicher <i>et al.</i> , 1995; Sener <i>et al.</i> , 1987
Isovaltrate	0.05 – 0.63	Granicher <i>et al.</i> , 1995; Hazelhoff <i>et al.</i> , 1979; 1981; Sener <i>et al.</i> , 1987
Acevaltrate	0.02	Hazelhoff <i>et al.</i> , 1979
Didrovaltrate	0.01 – 0.02	Granicher <i>et al.</i> , 1995; Sener <i>et al.</i> , 1987
IVHD valtrate	0.055	Granicher <i>et al.</i> , 1995


[0069] The data presented in Example 11 confirms the above information. In addition, according to a preferred aspect of the invention, a lower limit for total valepotriates in the extract may be set as a process condition. For example, valtrate and isovaltrate may be quantitatively monitored because they are present in significant quantities in the *V. officinalis* biomass. Total valepotriate levels in the extract produced by the current process should preferably be $\leq 0.1\%$. This ensures that the current extraction process consistently reduces valepotriates in the extract regardless of the starting concentration in the original biomass.

[0070] Major decomposition products of the valepotriates are the baldrinals, including baldrinal (from valtrate and acevaltrate) and homobaldrinal (from isovaltrate). See Bos, 1996; Houghton, 1997. As described in Bos, (1997), the baldrinals are chemically

reactive and may subsequently form polymers, although no evidence of polymerization was provided. Chemical structures of exemplary baldrinals are provided below.

X18816

	R
Baldrinal	COCH ₃
Homobaldrinal	COCH ₂ CH(CH ₃) ₂



[0071] Genotoxicity has been reported for both baldrinal and homobaldrinal. The compounds showed direct mutagenic effects *in vitro* in the AMES assay and the SOS-chromo-test (von der Hude, *et al.* 1986). In addition, metabolic degradation of ¹⁴C-methacetin was distinctly inhibited *in vivo* by baldrinal (26 mg/kg) and homobaldrinal (31 mg/kg) administered either IP or PO to mice (Braun *et al.*, Studies on the effects of Baldrinals on hemopoietic cells *in vitro*, 1986; 52: 446-450), indicating decreased liver function.

[0072] Accordingly, it is desirable to eliminate, or substantially reduce the level of, valepotriates and valepotriate decomposition products, such as baldrinals, in valerian extracts with respect to the levels of valepotriates in the root or biomass. The extraction method of the present invention achieves this objective, while simultaneously achieving the objective of extracting a measurable quantity of valerenic acid as described above.

Additional Definitions

[0073] As used herein, the term "valerian" refers to any plant of the Valerianaceae family possessing extractable valerenic acid in its roots, and therefore refers, at least to, the plant designated *Valeriana officinalis* L. or alternatively herein, *V. officinalis* L. This species

includes all recognized subspecies of *Valeriana officinalis* L. Some of these subspecies are also commonly referred to, in alternative taxonomic systems, as: *Valeriana exaltata* J.C. Mikan, *Valeriana nitida* Kreyer, *Valeriana palustris* Wibel, *Valeriana wolgenis* Kazak, *Valeriana grossheimii* Vorosch, *Valeriana collina* Wallr, *Valeriana Rossica* P.A. Smirn, *Valeriana spryngini* P.S. Smirn, *Valeriana angustifolia* Tausch, *Valeriana tenuifolia* Vahl, *Valeriana wallrothii* Kreyer, *Valeriana ucrainica* Demjan, *Valeriana sambucifolia* J.C. Mikan, *Valeriana excelsa* Poir, and *Valeriana officinalis* L. subsp. *excelsa* (Poir.) Rouy. Plants of the species *Valeriana officinalis* L. may be characterized as growing from a short rhizome to 2 m high, flowering, and then dying back again in the winter. These plants have pinnately-divided leaves with six to ten pairs of lance-shaped leaflets, and bear many small white or pink flowers in a dense head of several stalked clusters. These heads bear small (5 mm) tapered seeds.

[0074] As used herein, the term "valerian extracts" most generally refers to the composition isolated from the roots of plants of the Valerianaceae family according to a specified extraction procedure, and preferably refers to the composition isolated from the roots of valerian or *Valeriana officinalis* L. according to a specified extraction procedure. These extracts comprise essential oils, valerenic acids, valepotriates (iridoids), kessane derivatives, valerenone, valerenal, fatty acids, carbohydrates, and certain amino acids.

[0075] As used herein, the term "valerenic acids" refers to all chemically stable derivatives of valerenic acid. In its most limited and preferable connotation, this term refers to valerenic acid, acetoxyvalerenic acid, and hydroxyvalerenic acid (these three compounds, in aggregate, are also referred to herein as "VAs"). These compounds, either individually, in the aggregate, or based on their respective ratios, may be used as standards to evaluate the extraction processes herein described and/or to evaluate the plant from which the extracted roots have been obtained. Valerenic acid, in particular, may be used to verify that the roots extracted are of the species *Valeriana officinalis* L.

[0076] Valerenic acid (also referred to herein as "VA") is represented by the formula $C_{15}H_{22}O_2$, has a molecular weight of 234.33 amu, a UV λ_{max} at 218 nm with a $\log \epsilon$ of 4.232, and an $[\alpha]^{20}_D$ of -117.8° (c= 1.64, EtOH). Acetoxyvalerenic acid (also referred to herein as "AVA") is represented by the formula $C_{17}H_{24}O_4$, has a molecular weight of 292.35

amu, a UV λ_{max} at 217 nm with a log ϵ of 4.184, and has an $[\alpha]^{20}_D$ of -36.7° (c= 1.15, EtOH). Hydroxyvalerenic acid (also referred to herein as "HVA") is represented by the formula C₁₅H₂₂O₃, has a molecular weight of 250.34 amu, a UV λ_{max} at 212 nm with a log ϵ of 4.305, and has an $[\alpha]^{20}_D$ of -98.4° (c= 0.63, EtOH). Accordingly, UV measurements at 220 nm may be used to determine the content of the valerenic acids in a given sample or aliquot.

[0077] As used herein, the term "valepotriates" (these compounds, in aggregate, are also referred to herein as "VPs") refers to all chemically unstable, thermolabile triesters of polyalcohols having an iridoid structure that may be found in the roots of members of the Valerianaceae family. The most typical valepotriates, as that term is used herein, are the diene-type valepotriates, valtrate, acevaltrate, and isovaltrate. The decomposition products of valepotriates, for example, baldrinal and homobaldrinal are not within the definition of "valepotriates," but may be referred to as "valepotriate derivatives" or "valepotriate decomposition products." UV measurements at 200, 254, and 320 nm are preferably used to determine the content of valepotriates in a given sample or aliquot.

[0078] As used herein, the term "volatile oils" refers to all oils in *V. officinalis* that are volatile, for example valerenal, valerenol, camphene, bornyl derivatives, myrtenyl acetate, and kessane derivatives.

[0079] As used herein, the term "isolated" refers to the state of being free of other, dissimilar compounds with which the extracted components of the invention will normally be associated in their natural state, so that upon being "isolated" the pharmaceutically-active components comprise at least about 0.25%, about 0.5%, about 1%, about 2%, about 4%, about 5%, about 10%, about 20%, about 50%, and at least about 75% of the mass, by weight, of a given sample.

[0080] As used herein, the term "water" refers to water, and preferably to potable water, which includes purified and/or de-ionized water (DIW). Water, as used herein, may have dissolved within it a significant amount of any water-soluble solute, such as a salt or a sugar.

[0081] As used herein, the term "alcoholic" refers to a process of, or an extract obtained from, extraction in an alcoholic extraction solvent containing a significant percentage of alcohol. "Alcoholic extraction solvent" refers to extraction solvent having

greater than approximately 10% alcohol by volume, and preferably refers to extraction solvents having at least approximately 25%, 30%, 35%, 40%, 45%, or preferably 50% alcohol by volume. Most preferably, "alcoholic extraction solvent" refers to an extraction solvent having an alcohol content equal to or greater than approximately 70% by volume, and includes solvents that are 100% alcohol. Preferable, "alcoholic extraction solvent" refers to any C₁-C₆ alcohol, for example; methanol, ethanol, butanol or propanol, or any combination thereof, and most preferably refers to denatured ethanol (approximately 95% ethanol and approximately 5% methanol). The term "ethanol" should be understood as referring to denatured alcohol unless specifically identified otherwise.

[0082] As used herein, the term "roots" refers to all of the subterranean portions of a specifically or generically identified plant, including, but not limited to; the roots, the rhizomes, and the stolons of the specifically or generically identified plant. Where the term "roots" is not modified by a specifically or generically identified plant, it will be understood that the term refers to the roots of the species, and sub-species of, *Valeriana officinalis* L.

Preferred Extraction Processes

[0083] The extraction processes provided herein most generally involves heating a mixture of the roots and an alcoholic extraction solvent for an extended period of time to obtain valerenic acid and valerenic acid derivatives in the extract, and to significantly reduce the amount of valepotriates in the extract. These processes, when compared to currently known processes, significantly reduce the amount of valepotriates in the valerian extract, while maximizing the amount of valerenic acid and of valerenic acid derivatives. It is contemplated that the extract, isolated according to the method of the present invention, may ultimately be used for a pharmaceutically active formulation.

[0084] The method includes an extraction process. An overall method for preparing such a pharmaceutically active formulation is described in order to place the extraction process in the context of the preparation of the pharmaceutically active formulation. The following five steps comprise a preferred method for preparing such a formulation: Pre-Extraction Processing of the Root, Extraction, Drying and Milling of the Drug Substance, and Formulation of a Tablet or Capsule. Additional or alternative steps, as

well as the use of different pharmaceutical formulations, may be added without departing from this process.

[0085] Pre-Extract Processing of the Root. The roots may be prepared for extraction by grinding, chipping, or pulverizing them into a powder in a hammermill, or a like instrument, as will be appreciated by those of skill in the art. After such pre-extraction processing, preferably at least 70%, 75%, or 80%, and most preferably 85% or 90% of the mass of the roots pass through a Tyler 20-mesh screen. Also preferably, the raw or processed roots are stored in a durable non-reactive, preferably plastic, and more preferably polyethylene, container or containers. These containers may be doubly-lined with bags of like material and closed or closeable with a lid composed of like material.

[0086] Extraction. The valerian root, whether, as preferred, processed as described above or in an unprocessed state, may be added to an extraction solvent. Most preferably, the root is added in a ratio of approximately one kilogram to approximately five liters of extraction solution. The extraction solvent preferably is an alcoholic extraction solution, comprising between approximately 30% to approximately 100% (volume/volume; v/v) alcohol and between approximately 70% (volume/volume; v/v) to 0% (v/v) water. Preferably, the alcoholic extraction solvent comprises approximately 50% to approximately 100% (v/v), approximately 55% to approximately 95% (v/v), approximately 65% to approximately 85% (v/v), and approximately 65% to approximately 75% (v/v) alcohol. Specifically, the alcoholic extraction solvent may comprise approximately 50% (v/v), approximately 60% (v/v), approximately 70% (v/v), approximately 80% (v/v), approximately 90% (v/v) alcohol and approximately 100% alcohol. The alcohol used in the alcoholic extraction solvent is fully miscible in water, and is preferably denatured ethanol (95% ethanol + 5% methanol), but may be any C₁-C₆ alcohol, including but not limited to; methanol, ethanol, n-butanol, isobutanol, n-propyl alcohol, and isopropyl alcohol.

[0087] The mixture of root and alcoholic extraction solvent may be stirred by any mechanical device conventionally known for such purpose, including but not limited to; an overhead stirrer, a magnetic stirrer assembly, and/or a built-in stirrer, and may be suitable for or adapted to the particular extraction vessel employed. The mixture may be heated to between approximately 65°C and 85°C, and more preferably between approximately 70°C

and 80°C, or alternatively, the temperature of reflux. Specifically, the mixture may be heated to; 50°, 55°, 60°, 65°, 70°, 75°, 77°, or 80° or reflux. Various conventional methods may be used to heat the mixture, including but not limited to heating mantels or other resistive heating coils.

[0088] Preferably, the mixture is heated to any of the above-described temperatures for at least one, one and one-half, two, two and one-half, three, three and one-half hours, four, or up to five hours. These durations, most preferably the latter three durations, are selected to significantly reduce the level of valepotriates relative to the initial value, preferably at least a 50% reduction. (Final Value/Initial Value = Percent Reduction). More preferably the reduction is by 60%, 70%, 75%, 80%, 90%, 95%, and most preferably 100% of the detectable level of valepotriates. In the latter case, the valepotriate level is not detectable by conventional techniques. The final valepotriate level may be obtained and may also be compared to that found in commercial valerian extracts.

[0089] Optionally, the mixture may then be cooled, preferably to room temperature or alternatively to a temperature above room temperature, including; 30°C, 35°C, 40°C, 45°C, and 50°C. The solids may then be separated from the liquid (by filtration or centrifugation or any other conventional method for separation). The extraction vessel and the separated solids may be rinsed with the extraction solvent, described above. For such a rinse, from approximately four liters, three liters, two liters, or preferably one liter of extraction solvent may be used for each kilogram of root initially extracted.

[0090] Also optionally, the filtrate containing the extracted material may be concentrated to an oily consistency under reduced pressure, including approximately; 0.9, 0.8, 0.7, 0.6, and 0.5 atmospheres (atms), at a temperature above room temperature, including; 30°C, 35°C, 40°C, 45°C, and 50°C. Optimally, a final volume of approximately 0.15 liters for each kilogram of root extracted is obtained.

[0091] Addition of Excipient to Facilitate Drying. The concentrate may be mixed with an excipient to facilitate drying. The excipient may be chosen from any commercially-available excipient or mixtures thereof, but is preferably selected from the following; maltodextrin-NF, tricalcium phosphate, silicon dioxide, dicalcium phosphate, microcrystalline cellulose, solidified microcrystalline cellulose, various ion exchange resins

as will be understood by those of skill in the art, PVP/citrate, sodium citrate, pre-gelatinized corn starch (also known as Starch 1500), polyethylene glycol (PEG), sugar/polyol (also known as mannitol), TRIS buffer, sodium bicarbonate, porous silica, and combinations of the above-listed excipients and/or buffers, or other conventional excipient and any combination or mixture thereof as will be recognized by those of skill in the art. After addition of the excipient, the excipient will preferably comprise between approximately 10% and 40%, and more preferably between 20% and 25%, of the drug substance.

[0092] Drying and Milling of the Drug Substance. The concentrated valerian extract and excipient, if added, is dried under reduced pressure, including approximately; 0.9, 0.8, 0.7, 0.6, and 0.5 atms, at a temperature slightly above room temperature, including 30°C, 35°C, 40°C, 45°C, and 50°C. Optimally, the drying is continuous until water content is equal to or less than 15%, 10%, or 5%, as measured by Karl Fischer analysis. The dried mixture may then be milled to a target of 80%, 85%, 90%, or 95% by weight passing through a size-exclusion screen of 60-mesh, 70-mesh, 80-mesh, 90-mesh, or 100-mesh.

[0093] Optionally, drying of the extract may be accomplished by spray drying or any other conventional drying method as will be understood by one of ordinary skill in the art.

[0094] Certain of the constituents of *V. officinalis* L. have been identified as sesquiterpenes (in the volatile oils) and iridoids (known as valepotriates). The total content of volatile oil varies widely within a single species, and also may vary between different species. The oil typically consists of mixtures of monoterpane and sesquiterpene derivatives. The amount of valepotriates also varies. The process of the present invention has been shown to reduce the amount of valepotriates when compared to currently practiced valerian extraction processes.

[0095] When verifying the plant source and process of the extraction process of the present invention, valerenic acid, acetoxyvalerenic acid, and hydroxyvalerenic acid are preferably used as marker compounds for analysis of the extract and later formulations based on the extracts. The process of the present invention significantly reduces the amount of valepotriates, while optimizing the yield of valerenic acid, acetoxyvalerenic acid, and hydroxyvalerenic acid either alone or in the aggregate. Active constituents of the extract of

the present invention include, but are not limited to, valerenic acid and its derivatives (for example, acetoxyvalerenic acid and hydroxyvalerenic acid), kessane derivatives, valerenone, valerenal, small chain carboxylic acids, fatty acids, and amino acids; the extract may also contain sugars and trace amounts of other aliphatic acids, alkaloids, phenolic acids, flavonoids, free fatty acids, sugars, and salts.

[0096] The present invention is herein described in detail through a variety of examples. It will be understood by those skilled in the art that the invention is not limited to the specific examples provided herein. Furthermore, although various amounts of plant material, specifically, *V. officinalis* L roots, and various other parameters under which extractions are performed, including specific pH conditions, temperatures, durations, and extraction solvents, are specified in the following examples, it will be understood by those skilled in the art that the invention is not limited to these specific plants, and these specific amounts and/or parameters. It will also be understood by those skilled in the art that the amount or type of plant material, the pH, temperature, solvent, and/or duration of extraction may be varied, and that the resultant process will still achieve one or more of the objectives of the invention.

EXAMPLE 1

PROCESS FOR VALERIAN ROOT EXTRACTION

[0097] The following process yielded dried valerian root extracts. The process also provided a free-flowing powder containing 0.3 % to 0.8% valerenic acids and substantially reduced levels of valepotriates. Key process parameters were identified and acceptable ranges established. The process is as follows: chipped roots were extracted in 70:30 v/v denatured ethanol and potable water (EtOH/H₂O) maintained at approximately 70-75°C for three hours; the filtrate was cooled to approximately 20-30°C and the biomass was removed by filtration; the solvent was removed under vacuum at a temperature not greater than 40±5°C; the residual oil was added to a maltodextrin excipient; and the product was dried and milled.

[0098] The process parameters and their respective effects were as follows:

[0099] Temperature. The reduction of valepotriates was temperature-dependent, and proceeded more rapidly at higher temperatures. After three hours at 70°C, reduction of the main valepotriate UV peak was approximately 90%; after three hours at reflux temperature (79.81°C), the main valepotriate UV peak was reduced by over 99%. Recovery of valerenic acids was optimal at temperatures between 40°C and 80°C.

[0100] Solvent composition. 70%:30% (v/v) EtOH/H₂O was used as the extraction solvent. However, at EtOH concentrations between 50% and 100%, statistically similar recoveries of valerenic acids were recorded.

[0101] Solvent volume. Similar amounts of valerenic acids were extracted when from four to seven volumes (one volume being 1 milliliter/1 gram of roots) of extraction solution were used. A volume of five times the mass of the roots was preferred.

[0102] Amount of Excipient. The minimum amount of excipient that yielded a friable product was approximately 20% with respect to the weight of the roots. The following materials and reagents were used in this example: chipped valerian roots; denatured ethanol (SDAG-1 grade from Commercial Alcohols, Inc. containing 95% ethanol and 5% methanol) RM0077; maltodextrin (Maltrin® M-040) NF grade from Grain Processing Corporation; extraction solution: seven volumes of denatured ethanol per three volumes of potable water; Reeve Angel 202 filter paper.

[0103] The following procedure was performed in this Example.

[0104] Ground roots (in three quantities: 250.0±0.1 g, 500.0±0.1 g or 1000±0.1 g) of the plant *V. officinalis* L (Aromatics, Inc., 460 Lancaster Dr., Salem, Oregon) were obtained. A 3-neck round bottom flask was placed in a water bath, or, alternatively, in a heating mantle connected to a voltage regulator. A condenser and an overhead stirrer were connected to the flask. Using a graduated cylinder, five volumes of extraction solvent were measured, (with respect to the mass of the roots) using a 70% denatured ethanol : 30% potable water extraction solvent. The volumes were as recited in Table 2.

Table 2.

Volumetric Measurements of An Extraction Solvent For Various Root Masses

X1,0300

Weight of roots	Volume of 70% ethanol
250 grams	1250 milliliters
500 grams	2500 milliliters
1000 grams	5000 milliliters

[0105] Root powder and 70%:30% v/v EtOH/H₂O were added to the flask and the overhead stirrer was started. A 1.5 mL standard sample was removed and centrifuged. The temperature was continually monitored with a calibrated thermometer or thermocouple. When the temperature of the slurry reached 70-75°C, timing was started. 1.5 mL samples were removed at 30-minute intervals, and the temperature was maintained at approximately 70-75°C. After 3 hours \pm 15 minutes the slurry was cooled using external cold tap water to approximately 20-30°C. The slurry was filtered under a vacuum (5 in. Hg) through Reeve Angel 202 filter paper. A 15 cm filter was used for the 250 gram sample, a 20 cm filter for the 500 gram sample, and a 25 cm filter for the 1000 gram sample. These samples were washed using two volumes (with respect to the initial weight of the root powder) of 70%:30% v/v EtOH/H₂O. As the liquid left the surface of the filter cake, the cake wash was applied. After the cake wash was filtered, the cake was dried under full vacuum. Two 5.00 mL samples of filtrate were transferred into tarred disposable aluminum dishes for determination of the nonvolatile residue content of the filtrate. The samples were dried on a hotplate using the lowest heat setting and the drying was completed under a vacuum for approximately 1-2 hours at approximately 40 \pm 5 °C. The solvent was removed from the filtrate on a rotary evaporator connected to a house vacuum. A bath temperature, initially at 25-30°C, was increased gradually to 40 \pm 5 °C. The sample was concentrated until thick. Maltodextrin equal to 20% of the starting weight of the root powder was added, using a glass 10 mL pipette, while being rapidly stirred with a metal spatula until homogeneous. The maltodextrin root extract mixture was dried overnight in a drying oven using a house vacuum at 40 \pm 5 °C. The dried product was ground using a mortar and pestle.

EXAMPLE 2

PROCESS FOR VALERIAN ROOT EXTRACTION

[0106] Conditions identical to those detailed in Example 1 were used, except for the following: The temperature during the sample concentration was increased to $45\pm 5^{\circ}\text{C}$ rather than to $40\pm 5^{\circ}\text{C}$, and the sample was dried using a forced air drying oven with the temperature set at $40\text{--}50^{\circ}\text{C}$, rather than with a vacuum oven.

EXAMPLE 3

PROCESS FOR VALERIAN ROOT EXTRACTION

[0107] Conditions identical to those listed in Example 2 were created, except for the following: the flask used in the rotary evaporation step was rinsed thoroughly with 50 mL of extraction solution, and the rinse was concentrated in a 100 mL flask before it was added to the excipient.

EXAMPLE 4

PROCESS FOR VALERIAN ROOT EXTRACTION

[0108] Conditions identical to those listed in Example 1 were created, except for the following: One half of the filtrate was dried in two stages (i) 80% of the solvent was removed on a rotary evaporator at a vacuum of (16-25 mbar) and at a temperature of $\leq 35^{\circ}\text{C}$, and (ii) the remaining solvent was removed on trays in a forced-air drying oven at a temperature of $\leq 35^{\circ}\text{C}$ under atmospheric pressure; the concentrate was removed from the trays using an approximate equal weight of denatured ethanol; the ethanol-concentrate mixture was slurried with an amount of maltodextrin equivalent to 15% of the expected final powder weight; the spent biomass was re-extracted with 70% ethanol to determine whether a greater amount of valerenic acid is recovered under such conditions; lesser amounts of maltodextrin were used.

[0109] Also, a series of trials was carried out using 40%, 35%, 30%, and 25% maltodextrin to determine the minimum amount required to produce a solid product after the sample was dried; and 1% silicon dioxide was included in several samples to determine whether it reduces the amount of maltodextrin required to produce a solid dried product.

EXAMPLE 5

PROCESS FOR VALERIAN EXTRACTION

[0110] Conditions identical to those listed in Example 1 were created, except for the following: The root-solvent mixture was refluxed for 3 hours (77-79°C) rather than at 70-75°C as in the previous four demonstration runs; the amount of maltodextrin used was reduced by approximately two-thirds, i.e., 67 g rather than 200 g was used; the product was dried in a vacuum oven at 50°C under a vacuum of 25-26 in. of mercury (Hg).

[0111] Summary of the Results from Examples 1 through 5. Examples 1, 2, 3, 4, and 5 are meant to exemplify protocols and process parameters under which the objectives of the present invention may be achieved. Certain of the process parameters of Examples 1, 2, 3, 4, and 5 of the Valerian Root Extraction Processes are provided in Table 3.

Table 3.
Demonstration Run Methods and Parameters

11/03/20

Example #	Scale (g of roots)	Extraction Temp.(°C)	Filtrate Concentration Method	Drying Method
1	250	70-75	Rotary evapor. (<40°C)	Vac. Oven at 40°C
2	250	70-75	Rotary evapor. (<45°C)	Forced air at 40-50°C
3	500	70-75	Rotary evapor. (<45°C)	Forced air at 50°C
4	1000	70-75	Rotary evapor. (<35°C) + Forced Air (35°C)	Not dried
5	1000	77-79 (Reflux)	Rotary evapor. (<50°C)	Vac. Oven at 50°C

*Only one-half of the filtrate was concentrated by this method

[0112] Effects of extraction temperature. As shown in Table 4, valepotriate levels decreased during the heating of the extraction mixtures. The reduction in valepotriate levels was much faster at reflux temperature (77-79°C) than at 70-75°C. After three hours the valepotriate levels in Example 5 were 23%-30% of those in Example 1, 2, 3, and 4. The levels of valerenic acids were not affected by extraction temperature or time. They reached their maximum level by the time the extracts attained the target temperatures and remained constant during the three hour heating period. Table 10 shows the average levels of total valerenic acids observed in the unfiltered extracts. The amounts appeared to be greater in

Examples 1 and 2 than in Examples 3, 4, and 5. However these differences may be attributed to differences in the standard curves employed for acetoxyvalerenic acid.

Table 4.

Peak Areas (254 nm) for Valepotriates with Retention Time =29 Minutes (5X dilutions)

Time (hour)	Example 1	Example 2	Example 3	Example 4	Example 5
0	438,602	432,013	284,766	316,368	167,548
0.5	213,695	212,836	151,955	185,597	54,976
1.0	102,824	105,555	80,681	99,191	19,205
1.5	50,250	52,353	39,294	55,816	8,238
2.0	29,430	25,523	22,723	32,193	4,480
2.5	16,243	16,274	15,391	19,315	3,226
3.0	10,976	11,345	10,069	12,690	2,972

Table 5.

Valerenic Acids Content in Unfiltered Extracts

Example #	Scale (g of roots)	Average Concentration of VAs (μ g/mL)	Total VAs in Extract (mg)	% roots' weight
1	250	410	512	0.205
2	250	400	500	0.200
3	500	339*	847	0.169
4	1000	361*	1805	0.180
5	1000	359*	1793	0.179

*New standard curves were utilized for these measurements.

[0113] Effects of temperature and vacuum on valerenic acid recovery. The low recovery of valerenic acids in Example 1 (see Tables 5 and 6) was initially attributed to their volatility and loss under the effects of vacuum and heat during the concentrating and drying steps. In subsequent Examples 2, 3, 4, and 5, changes were made in these steps as outlined in Table 3. For example, forced air drying rather than vacuum oven drying was used in Examples 2 and 3. Although the yields of valerenic acids improved slightly (Table 6), this improvement was attributed to better rinsing of the evaporator flask.

[0114] The effects of temperature and vacuum on valerenic acid recovery were investigated in a small-scale experiment carried out with aliquots of filtrate from Example 4. Samples of filtrate were dried under the conditions described in Table 3 and then reconstituted and analyzed for valerenic acids. The results indicated that there were no significant losses, even at 50°C under vacuum for 72 hours, and that a vacuum tray drying could be used without appreciable loss of valerenic acids. This result was confirmed in Example 5 where the product was dried at 50°C under a house vacuum and the valerenic acid recovery was 92% (Table 7). However, under these conditions the drying process was very slow, requiring 3.5 days. The two step concentrating procedure used in Example 4 was determined to be non-optimal due to the time required to complete the forced air drying and due to the difficulty of mixing the excipient with the residue.

Table 6.
Final Powders Analyses

X1, 0340

Example #	Scale (g roots)	Powder Weight (g)	% VAs	Total VAs (mg)	% Recovery*
1	250	95.7	0.346	331	65
2	250	94.7	0.446	423	85
3	500	191.3	0.388	742	88
4	1000	Not appl.	Not appl.	Not appl.	Not appl.
5	1000	267.0	0.616	1643	92

*expressed as a percentage of the valerenic acids content of the unfiltered extracts

Table 7.
Valerenic Acids Recovery in Small-Scale Drying Experiments

J1,0350

Drying Method	Valerenic Acids in Reconstituted Samples (µg/mL)
None (Filtrate)	54.2
Room temp., 25-26 in. vacuum, 72 h	54.4
35-43°C, 1 atm, 72 h	53.2
50°C, 25-26 in. vacuum, 72 h	53.4
50°C, 25-26 in. vacuum + maltodextrin, 72 h	53.7

[0115] Extracted solids. Table 8 provides a summary of the total dissolved solids (TDS) in the filtrates (determined using 5.00 mL samples) and the weight of solids (minus excipient) recovered in the final dried product. The extracted solids in the final product ranged from 17.9% to 20.0% of the weight of the roots.

Table 8.
Extracted Solids

J1,0351

Example #	Scale g of roots	TDS in Filtrate (% of root weight)	Final powder weight less weight of excipient (% of roots' weight)
1	250	55.8 g (22.3%)	45.7 g (18.3%)
2	250	46.1 g (18.4%)	44.7 g (17.9%)
3	500	92.2 g (18.4%)	91.3 g (18.3%)
4	1000	199.5 g (20.0%)	Not Applicable
5	1000	186.0 g (18.6%)	200. g (20.0%)

[0116] Amount of Excipient Added. In Examples 1, 2, and 3 the final product contained approximately 52% maltodextrin by weight. Small-scale trials using portions of the filtrate from Example 4 indicated that the amount of maltodextrin could be reduced to 25% of the final powder weight. In Example 5 the amount of maltodextrin was reduced accordingly and this resulted in a substantial increase in the weight percentage of valerenic acids in the final powder (Table 18).

- [0117] From the above data, the following conclusions were drawn:
- [0118] The optimum temperature for substantial reduction of valepotriate levels was reflux temperature (77.79°C).
- [0119] Losses of valerenic acids were not significant at 50°C under vacuum.
- [0120] The maltodextrin content may be reduced to 25% of the final powder weight.

EXAMPLE 6

EXTRACTION IN WATER DOES NOT YIELD VALERENIC ACIDS

- [0121] The method of Cerise *et al.* (U.S. Patent 5,211,948) was used to attempt to extract valerenic acids from valerian root powder.
- [0122] Valerian root powder was obtained from Triarco Industries, Lot LA019, lot size 25 kg. 10 g of valerian root powder was suspended in 60 mL of deionized water (DIW), and placed in a 70°C bath and stirred with an overhead stirrer for 1 hour. The sample was then cooled in tap water to 20°C. 2.5 grams of Celite Hyflo Super Cel ("HyFlo") was added and the slurry filtered through a 5.5 cm filter precoated with 2.5 g Hyflo. Vacuum = 5". Cake Wash = 40 mL of DIW added after 3 min. Filtrate volume = 85 mL. Color— very dark brown. Total filtrate time = 2.5 min. The solid content of the filtrate was determined as follows: 1.00 mL of filtrate was added to an aluminum dish and evaporated to dryness on a hotplate. The dish was then dried for 1 hour in a vacuum oven at 70°C under house vacuum. The disk was then cooled in a desiccator.

- [0123] Water was evaporated from the bulk sample on a rotary evaporator at a temperature of approximately 50°C. The contents were emptied into a graduated cylinder, rinsed with de-ionized water (DIW) to a total volume of 24 mL. Twenty-four mL of 95% ethanol: 5% methanol was added. After 1 hour the sample was centrifuged, the supernatant was decanted, and the solid content was determined. The dried extract was dissolved in 20 mL of DIW and lyophilized overnight at 60°C. Drying was completed at 90°F for 1 hour. The lyophilized samples were pulverized and analyzed by HPLC. There were no significant amounts of valerenic acid or acetoxyvalerenic acid present, as determined by HPLC or UV analysis.

[0124] The valerian root powder does not contain water-extractable valerenic acid, acetoxyvalerenic acid, or hydroxyvalerenic acid.

EXAMPLE 7

EXTRACTION IN WATER DOES NOT YIELD VALERENIC ACIDS

[0125] The following procedure was used to determine the yield of valerenic acids from valerian root powder extracted at room temperature with a 50%/50% (v/v) mixture of alcohol and water, and to compare said extraction with a 100% water extraction.

[0126] In a first sample, ten grams of valerian root powder was stirred at room temperature with 30 mL of 95% ethanol:5% methanol plus 30 mL of deionized water for 2 hours with a magnetic stirrer. One mL of the suspension was centrifuged and a 250x dilution of the suspension was prepared in deionized water.

[0127] A second sample of powder root was prepared from the same lot in deionized water in the following manner: 200 mg of root powder was dissolved in 5 mL of deionized water. Absorbance spectra of the two samples were obtained and indicated different amounts of valerenic acid in the two samples. While the 50% ethanol extraction showed an absorbance maximum at 220 nm, the water extraction showed no absorbance maximum at 220 nm. The respective absolute intensities were 1.15 and 0.24.

[0128] This result confirms that the water based extract of the root of valerian does not contain valerenic acids.

EXAMPLE 8

EXTRACTION IN WATER DOES NOT YIELD VALERENIC ACIDS

[0129] Between 200 and 250 mg of root powder were added to three separate 10 mL volumetric flasks. In the first flask, deionized water was added. To the second flask, an equal volume of 50% ethanol/50% water (v/v) was added. To the third flask, an equal volume of HPLC grade pure ethanol was added. Each flask was stirred at room temperature for 15 min and then filtered through 0.45 μ m filters into HPLC vials. The resulting HPLC analysis led to the approximated results shown in Table 9.

Table 9.
Results of Example 8

JH 380

Solvent	Total Valerenic Acids (Relative Intensity)
Pure water	0.085
50% ethanol	0.24
Pure ethanol	0.20

[0130] These results indicate that 100% water is not viable to use for extraction of valerenic acids. However, both 50% ethanol, and pure ethanol gave reasonably good results with respect to valerenic acids extraction.

EXAMPLE 9

EXTRACTION IN WATER DOES NOT YIELD VALERENIC ACIDS—
COMPARISON BETWEEN A PRIOR ART EXTRACTION METHOD AND A METHOD
OF CURRENT INVENTION

[0131] The process described in the U.S. Patent No. 5,211,948 was duplicated and the precise amounts of the three previously described valerenic acids were quantitated by liquid chromatography. First, 25 mg of finely powdered roots of *V. officinalis* were extracted with 150 mL of water heated to an average temperature of 70°C for a period of 4 hrs. The water extract was separated from the ground root and concentrated at 50°C under vacuum to a dry matter content of about 14%. To this concentrate an equal volume of ethanol was added to attain a final concentration of 50% ethanol. After standing for a period of 8 to 20 hr at room temperature, the precipitate formed was removed. The above-described extraction process was repeated two more times with 100 mL of fresh water each time and heated for 3 and 2 hr, respectively. Each extract was analyzed for total valerenic acids using an HPLC method and the results are summarized in Table 15.

[0132] To determine whether the valerenic acids remained behind with the valerian root, the “spent” valerian root biomass was extracted subsequently with 330 mL of denatured ethanol (about 70% ethanol, final concentration) for 10 to 15 min. The ethanolic extract was analyzed for valerenic acids and the results, shown in the last row of Table 10.

[0133] The process described in the current invention was duplicated and the amounts of total valerenic acids were quantitated by liquid chromatography, as follows: 25 gm of finely powdered roots of *V. officinalis* was extracted with 125 mL of 70% denatured ethanol by refluxing at 70°C for a period of 5 hr. The hydroalcoholic extract was separated from the biomass and analyzed for total valerenic acids by an HPLC method. The results are summarized in Table 11.

Table 10.
Extraction of Three Valerenic Acids - Prior Art Process

8/1/03 90

Sample Description	Hydroxy- valerenic acid (mg)	Acetoxy- valerenic acid (mg)	Valerenic acid (mg)	Total Valerenic acids* (mg)
Extract #1	0.144	0.575	0.366	1.085
Extract #2	0.421	1.36	0.59	2.371
Extract #3	0.407	1.2	0.338	1.945
Total from Extractions	0.972	3.135	1.294	5.401
Total Remaining in Spent Biomass **	1.71	17.68	21.04	40.43

*Sum of Hydroxy-, acetoxy- and valerenic acids

**Valerenic acids extracted from spent biomass with 70% ethanol

Table 11.
Extraction of Three Valerenic Acids

X1,0400

Sample Description	Hydroxy-valerenic acid (mg)	Acetoxy-valerenic acid (mg)	Valerenic acid (mg)	Total Valerenic acids (mg)
Present Method	1.34	25.43	23.79	50.56

[0134] The results of this example (see Table 10 and 11) demonstrate that total valerenic acids (hydroxyvalerenic, acetoxyvalerenic, and valerenic acid) of *V. officinalis* root are poorly extracted by the process described by the U.S. Patent No. 5,211,948, and that most of the acids remain behind in the spent biomass. Based on these results, it is concluded that valerenic acids are poorly soluble in water. Thus, the process described in the prior art patent does not effectively extract the valerenic acids from *V. officinalis* root.

[0135] In contrast, the process of the present invention, as shown in Table 11, is very efficient in extraction of total valerenic acids. A comparison of the extraction efficiency by these two processes, as summarized in Table 12, shows that the prior art process is only about 11% as efficient as the current process in extracting valerenic acids.

Table 12.
Recovery Of Valerenic Acids—Prior Art Process vs. Method Presented Herein

X1,0401

Sample Description	Hydroxy-valerenic acid (mg)	Acetoxy-valerenic acid (mg)	Valerenic acid (mg)	Total Valerenic acids (mg)
Present Invention	1.34	25.43	23.8	50.6
Prior Art Process	0.97	3.13	1.3	5.4
Isolation Efficiency* (%)	72.5	12.3	5.4	10.7

*Efficiency of Prior art process as compared to Present Invention

EXAMPLE 11ANALYSIS OF VOLATILE OILS IN VALERIAN SAMPLES PRODUCED BY PRIOR
ART PROCESS AND THE CURRENT PROCESS

[0136] Samples obtained using the process of the U.S. Patent No. 5,211,948 and the current process (see Table 10 and 11 for sample description) were analyzed for the presence of volatile oils. Qualitative analysis of volatile oils was done on a Finnigan Trace GCMS instrument using a Supelco SPB-5 30m x 0.25mm x 0.25 μ m column (length, diameter, packing thickness) maintained at a temperature of 280°C. Eluting peaks were monitored as positively charged mass units.

[0137] The chromatograms obtained according to the '948 patent clearly show that extraction of valerian root three times with hot water, does not yield any volatile oil peaks (the peak eluting around 40 min corresponds to siloxane, which is used as column coating). In contrast, the current process yielded numerous volatile oil peaks. To show that volatile oils are not destroyed by the '948 process but still remain with the biomass, the spent biomass was extracted with 70% ethanol. Numerous volatile oil peaks were observed in the chromatograms of the spent biomass, clearly indicating that the '948 process is unable to extract the highly polar volatile oils from the valerian roots

[0138] The volatile oil component of *V. officinalis* makes a major contribution towards the sedative activity of valerian extract (Houghton 1997). Thus, the current process will yield a product rich in volatile oil and thus would be superior to the product obtained by the process of U.S. Patent No. 5,211,948.

EXAMPLE 11

[0139] Two lots of *V. officinalis* root were analyzed for Valepotriate content as follows. At the time of analysis, approximately 6 months to approximately 18 months had passed from the date of harvesting. Valtrate and isovaltrate were measured in each biomass sample utilizing an HPLC method coupled to a diode-array detector, while didrovaltrate (which is present in trace amounts) was analyzed using a more sensitive LC/MS/MS method.

Reference standards, made at Ancile Pharmaceuticals, Inc., San Diego, CA, for each of these valepotriates were used, and Standard HPLC and LC/MS/MS methods were employed as follows : The valepotriates isovaltrate and valtrate were analyzed by an HPLC method using a C-18 reverse phase column (4.6 x 250 mm, 4 μ m particle size) Valepotriates were monitored at their UV absorbance maximum of 254 nm. The retention time of isovaltrate and valtrate under the LC conditions were about 28.9 and 30.1 min, respectively. Didovaltrate was analyzed by a LC/MS method using a C-18 (3 x 150 mm, 3 μ m particle size) column. Didovaltrate was detected by Selective Ion Monitoring in MS2 positive ion mode. Retention time under the LC condition was about 8.0 min.

[0140] Valepotriate peaks were identified based on their relative elution times as compared to the standards as well as their characteristic UV absorption spectrum. See Bos R. et al., Analytical aspects of Phytotherapeutic Valerian preparation, 1996; 7:143-151) and/or molecular mass. The quantitative results are summarized in Table 13. Valtrate and isovaltrate were shown to be present in a low amount (< 0.5%), whereas the monoene valepotriate, didovaltrate, was present in trace quantities (< 0.005%). In addition, analysis of the extract, revealed that following the extraction process, the content of didovaltrate is below the limit of detection (< 7 ppm) of LC/MS/MS methods.

Table 13.
Valepotriate Content in *V. officinalis* Dried Roots

X 100/30

V. officinalis	Content in dried root (% w/w)		
	Isovaltrate	Valtrate	Didovaltrate
Sample 1	0.40	0.049	0.0045
Sample 2	0.19	0.045	0.0022

EXAMPLE 12

[0141] As described earlier, the present extraction process significantly reduces the levels of valepotriates in the extract with respect to the content in *V. officinalis* biomass.

To demonstrate that this process does not result in the accumulation of potentially toxic baldrinals, the extract was analyzed for its baldrinal and homobaldrinal content.

[0142] Homobaldrinal is present in an extract according to the invention at only 5.9 ppm, and the level of baldrinal is below the limit of detection of the assay (< 3 ppm). Similar results were obtained for the content of isovaltrate and valtrate in this extract. In contrast, the starting biomass contained 4000 ppm isovaltrate and 490 ppm valtrate. This data, summarized in Table 14, demonstrates that the current extraction process significantly reduces valepotriate levels but does not result in the accumulation of baldrinals. The levels of homobaldrinal and baldrinal may be collected to confirm, across manufacturing runs, that the baldrinals are not produced during the extraction processes.

Table 14.

Levels of Valepotriates and their Degradation Products in the Current Extract

H.0430

Compound	Level in the Extract (ppm)	
	The Starting Biomass	The Extract
Valtrate	490	ND
Isovaltrate	4000	<24
Baldrinal	NT	ND
Homobaldrinal	NT	5.9

ND: Not detected

NT: Not tested

EXAMPLE 13

TEMPERATURE AND VOLUME DEPENDENCE OF EXTRACTION (30-50°C)

[0143] This Example was conducted (1) to determine the amount of valerenic acids extracted from chipped valerian root at 30°C, 40°C, and 50°C; (2) to determine the effect of using a large volume of extraction solvent; (3) to determine if homogenizing the mixture releases valerenic acids more efficiently than stirring; (4) to determine if using absolute ethanol rather than 95% ethanol:5% methanol effects the extraction process; (5) to

evaluate percolation of the extraction; and (6) to determine if heating an extract at 42°C efficiently destroys valepotriates.

[0144] The same materials as used in Examples 1-5 are used in this Example.

[0145] Ten grams of chipped root was stirred with 60 mL of extraction solvent using an overhead stirrer. 70% ethanol was used as the extraction solvent. Separate samples were prepared and stirred in the calibrated water bath for 1 hour. Temperatures of 30°C, 40°C, and 50°C were used. Samples were covered with parafilm to prevent solvent evaporation. After 1 hour, samples were cooled to room temperature under cold tap water. Samples were filtered through 5.5 cm filters and the filter cake rinsed with 30 mL of the alcoholic extraction solvent. The solid content was determined by evaporating 3 mL aliquots on aluminum dishes using a hotplate and then drying in a vacuum oven at 55°C for 1.5 h. Before HPLC analysis, a portion of each filtrate was diluted 10x with 70% ethanol and filtered through a 0.2 micron syringe filter. Portions were also diluted 50x in deionized water and UV/VIS spectra were obtained.

[0146] The samples, designated A, B, C, D, E, F, G, were differentiated as follows: Sample A was extracted at 30°C, Sample B was extracted at 40°C, Sample C was extracted at 50°C, Sample D was extracted in 90 mL of extraction solvent at room temperature, Sample E was extracted at room temperature, Sample F was extracted in absolute ethanol, and Sample G was extracted at 43°C for two days. Results are shown in Table 15 and 16.

Table 15.
Extracted Solids

JH, JH

Sample	Volume (mL)	Weight %	A _{275nm}	A _{320nm}
A	75	16.6	1.055	0.724
B	71	17.5	1.301	0.433
C	68.5	17.0	1.361	0.432
D	107.5	18.8	0.886	0.545
E	78	13.2	1.220	0.803

Table 16.
HPLC Results of This Example

1/10/50

Sample	HVA	AVA	VA	Total VAs	VP ht/ VA ht**
A (30°C) µg/mL	1.84	123	94.4	218	0.66
mg	0.15	9.22	7.08	16.4	
weight %	0.002	0.092	0.071	0.164	
B (40°C) µg/mL	2.90	145	122	282	0.61
mg	0.28	11.1	8.66	200	
weight %	0.0003	0.111	0.087	0.200	
C (50°C) µg/mL	3.78	161	123	238	0.51
mg	0.26	11.0	8.4	19.7	
weight %	0.003	0.110	0.084	0.197	
D (Room Temp.) µg/mL	1.74	97.9	77.6	177	0.69
mg	0.187	10.5	8.34	19.0	
weight %	0.002	0.105	0.083	0.190	
E (Room Temp.) µg/mL	2.14	137	105	244	0.69
mg	0.17	10.7	8.2	19.1	
weight %	0.002%	0.107%	0.072%	0.191%	
F (EtOH) µg/mL	2.14	182	139	232	0.64
mg	0.013	1.09	0.83	1.93	
weight %	0.001%	0.109%	0.033%	0.193%	
G (43°C) µg/mL	2.48	117	96.4	216	0.13
mg	0.186	8.78	7.23	16.2	
weight %	0.002%	0.088%	0.072%	0.162%	

**Ratio of Valepotriate peak at 29 minutes to Valerenic acid peak.

[0147] From this Example, it was determined that the optimum temperature for extracting valerenic acids is 40-50°C. The use of larger volumes of extraction solvent extracted about 15% more valerenic acids, and valerenic acids are stable in solution at 42°C for 2 days, while valepotriates are not.

EXAMPLE 14

TEMPERATURE DEPENDENCE OF EXTRACTION (60°C)

[0148] This Example was conducted to evaluate an extraction at 60°C and to determine if similar amounts of valerenic acids and valepotriates are extracted as compared to extraction at lower temperatures.

[0149] Materials as used in Examples 1, 2, 3, 4, and 5 are also used in this Example.

[0150] The extraction of 15 g of ground roots with 75 mL of 70% ethanol was carried out in a 250 mL glass three-necked flask, equipped with a condenser and overhead stirrer. After 1 hour at 60°C, the sample was cooled and filtered through a 5.5 cm filter. 30 mL of cake wash was used. A 5x dilution was used for HPLC analysis. The dry weight was determined by evaporating 3 mL of filtrate in an aluminum pan on a hotplate and then placing the pan in a vacuum oven at 55°C for 1 hour. The results are shown in the Table 17.

Table 17.

Results of Example 14.

X1000

	HVA	AVA	VA	Total	VP ht/ VA ht**
µg/mL	3.661 g	181.2	150.0	335	0.51
total	0.329	16.3	13.5	30.1	
weight %	0.002	0.109	0.090	0.201	

[0201] **Ratio of Valepotriate peak at 29 minutes to Valerenic acid peak.

[0151] From the data obtained in this Example, it was determined that, (i) at 60°C, the same amount of valerenic acids was extracted (approximately 0.2%) as at 40°C, but more solids were extracted at the higher temperature, (ii) significantly less valepotriates were extracted at 60°C, (previous peak ratios were 0.60 - 0.65), suggesting that longer extraction times and/or higher temperatures were effective in eliminating valepotriates.

EXAMPLE 15

TEMPERATURE DEPENDENCE OF EXTRACTION (80°C)

[0152] In this Example, six samples of 100 grams of chipped roots were added to six aliquots of 500 mL of 70% ethanol, and were stirred at 80°C for the following times: zero, one, two, two and one-half, three, and three and one-half hours. For each of these samples, an absorbance at 220 nm and 200 nm was observed to determine if the valerenic acid and acetoxyvalerenic acid concentrations varied. The valerenic acid and acetoxyvalerenic acid concentrations did not vary.

[0153] Furthermore, the concentration of valepotriates was determined for the two and one-half, three, and three and one-half hours samples. It was determined that there was no significant difference in percent reduction of valepotriates between two and one-half, three, and three and one-half hours. Accordingly, it was determined that extraction times ranging from approximately two and one-half, to three and one-half hours could be employed at an extraction temperature of 80°C.

EXAMPLE 16

pH DEPENDENCE OF EXTRACTION

[0154] This Example was conducted to evaluate the effects of acidic pH and/or 70°C temperature on valepotriate content, and more specifically to evaluate whether the valepotriates in root extracts could be removed by heating the extracts at 70°C and maintaining the pH at 2-3.

[0155] Fifteen grams of ground root was added to 25 mL of 75% ethanol at room temperature, and the pH was adjusted to 2.2 with 1 N HCl. The following experiments were conducted:

[0156] Experiment A: Fifteen grams of ground root was added to 75 mL of 70% ethanol at room temperature, and the pH adjusted 2.2 with 1 N HCl. Samples were removed at; Time = 1 hour and Time = 2 hours, centrifuged, and the supernates were diluted 5x for HPLC analysis. The pH drifted upwards after 1 hour. Additional acid was added; a total of 7 mL was added. After 2 hours, the pH was adjusted to pH 6 with 1 N NaOH. Again, the pH drifted (downward) and was monitored and adjusted every 15 minutes.

[0157] Experiment B: Fifteen grams of ground root was added to 75 mL of 70% ethanol, and was warmed to 70°C in a water bath. Also in the water bath was a 3-neck 250 mL flask plus a condenser and an overhead stirrer. Samples were taken at time = 0, 1, and 2 hours then centrifuged and diluted as in Experiment A.

[0158] Experiment C: Identical to Experiment 1, except 7 mL 1 N HCl was added at time = 0 and the pH was checked with pH paper to ensure that it was between pH=2 and 3; and rechecked after 1 hour. Samples were removed at time = 0, 1, and 2 hours. The pH was adjusted to 6 with NaOH after 2 hours.

[0159] Experiment D: the sample obtained from Experiment 2 was rinsed with 30 mL cake wash; the pH of the filtrate was adjusted to 2.3 with 1 N HCl. The sample was stirred for 1 hour. The results of Experiments A, B, C, and D are shown in Table 18.

Table 18.

pH Dependence of Extraction

10480

Time (hour)	VA ($\mu\text{g/mL}$)	VA. peak area at 220 nm	VP peak area at 220 nm (29 min peak)	Ratio of VP/VA**
Experiment A				
0	28.7 x 5	162,404	79,342	0.49
1	31.0 x 5	175,229	92,607	0.53
2	32.3 x 5	183,157	86,761	0.47
pH readjust.	35.0 x 5*	198,278*	135,803*	
Experiment B				
0	34.8 x 5	196,699	80,889	
1	35.8 x 5	202,532	43,476	
2	39.1 x 5	221,412	11,388	
Experiment C				
0	31.6 x 5	178,843	63,650	
1	33.4 x 5	188,808	21,815	
2	32.9 x 5	185,843	13,618	
pH readjusted	31.0 x 5	175,258	12,852	
Experiment D				
0	25.4	143,977	11,631 (5810)	
1 h	26.1	147,925	12,955 (7233)	

**Ratio of Valepotriate peak at 29 min to Valerenic acid peak.

[0160] From the data obtained in this Example, it was determined that, at room temperature, adjusting the pH to 2-3 had a small but immediate effect on the valepotriate

peak with a retention time of 29 minutes. Specifically, this peak has an area that is typically approximately 60-65% of that of the valerenic acid peak at 220 nm. However, at pH = 2-3, the peak area was 50% of the valerenic acid peak area. The reduction in area was the same at extraction times of two hours and zero hours. Also heating the extract at 70°C destroyed the valepotriate peak. Each hour saw the peak area reduced substantially. At pH 2-3 and 70°C, the valepotriate destruction occurred substantially faster during the first hour. Notwithstanding the results of these Examples, the extract process may be performed at a pH greater than about 3.0, greater than about 5.0, or greater than about 7.0.

EXAMPLE 17

EFFECT OF REFLUX AND THE DURATION OF REFLUX ON THE EXTRACT

[0161] This Example was conducted to determine whether the content of valerenic acids, of valepotriates, and of extracted solids are effected after refluxing ground valerian root for 3 hours in 70% ethanol.

[0162] One hundred grams of ground root was added to 500 mL of 70% ethanol, transferred to a one liter, 3 neck flask equipped with a condenser and an overhead stirrer, and heated in a water bath. Samples were removed at time = zero, one, two, and three hours respectively. Samples A, B, C, and D. After 3 hours the slurry was filtered on a 15 cm filter (RA202) and the filter cake was washed with 2 mL of 70% ethanol. Three 5 mL samples of filtrate were dried in aluminum dishes to calculate extraction efficiency. The rest of the filtrate was concentrated in a roto-evaporator.

[0163] The obtained samples were centrifuged. A portion of the supernatant was diluted 100x in extraction solvent and a UV/VIS spectrum was obtained. The remaining filtrate was mixed with 20 grams of maltodextrin and dried at 35°C, at reduced pressure, overnight. The results are shown in Table 19, 20, 21 and 22.

Table 19.

Extracted solids

11.0500

Sample	Tare Weight	Gross Weight	Net Weight	Average
A	1.8822 g	2.0365	0.1543	
B	1.8613 g	2.0151	0.1538	0.1540
C	1.8721 g	2.0260	0.1539	

Table 20.

Valerenic Acids: (weight %)

11.0501

Sample	Time	HVA	AVA	VA	Total
A	0	0.0023	0.099	0.075	0.176
B	1 h	0.0036	0.122	0.092	0.213
C	2 h	0.0041	0.121	0.095	0.226
D	3 h	0.0055	0.125	0.099	0.230

Table 21.

Absorbance at Various Wavelengths

11.0502

Sample	Abs _{275nm}	Abs _{320nm}	Abs _{400nm}	Abs _{600nm}
A	0.64786	0.52651	8.2934e-2	1.6159E-2
B	0.83918	0.74047	0.12043	3.4679E-2
C	0.83128	0.74164	0.10537	2.1706E-2
D	0.82511	0.73693	0.10685	2.9453E-2

Table 22.

Retained Valepotriates

11.0503

Sample	UV Peak Area
A	239,953
B	20,245
C	6,484
D	4,156

[0164] Table 23 shows data used on the refluxed root powder in this Example. The data in Table 23 were used as a standard.

Table 23.
Data Used On The Refluxed Root Powder

X10510

Sample		HVA	AVA.	VA.	Total
#1 200mg/10 mL	µg/mL	2.39	39.47	29.60	71.96
	wt %	0.12	0.200	0.148	0.360
#2 220.9 mg/103 mL	µg/mL	1.14	43.7	33.2	72.04
	wt%	0.005	0.198	0.150	0.353
	Avg. wt. %	0.008	0.144	0.149	0.356

[0165] From the data obtained in this Example, it was determined that refluxing was an effective way to remove valepotriates. However, the yield of valerenic acids in the dry powder obtained from reflux was significantly lower than when the extraction was carried out at 70°C.

EXAMPLE 18

EFFECT OF HEATING DURATION ON EXTRACT VALEPOTRIATE CONTENT

[0166] In this Example, the extraction mixture was heated at reflux for three and one-half hours (Table 24). This Example was conducted to determine if there are significant differences in the levels of valepotriates between three and one-half hours of reflux and the durations exemplified in the previous example.

Table 24.

X10511
Levels of Valepotriates After Heating the Extraction Mixture for 2.5, 3.0, and 3.5 Hours

Lot	Time (h)	µg/mL (x 5)			Valepotriate R _f =29.5 nm Peak area at 253 nm
		HVA	AVA	VA	
RK27A	2.5	0.06	40.2	31.2	3652
RK27B	3.0	0.9	40.1	31.3	2937
RK27C	3.5	0.9	40.4	33.3	3066

Total VA = $74.6 \times 5 \times .500 \text{ mL} = 186 \text{ mg}$
Einal Powder

Table 25.

Percentage of valepotriates recovered after heating extraction mixture

Sample wt.	% HVA	% AVA	% VA	Total VAs
227.4	0.004	0.135	0.107	0.246
218.0	0.0004	0.137	0.107	0.245

X 10520
 Total val. acids = $0.246 / 100 \times 35.42 \text{ g} = 87 \text{ mg}$ (46.3%) valerenic acid peak at 254 nm.

[0167] From the data obtained in this Example, it was determined that there was little change in valerenic acid and valepotriate content in the extract when comparing reflux for three, and three and one-half hours and the durations exemplified in the previous example.

EXAMPLE 19

USE OF AN EXTRACT OF THE ROOT OF THE PLANT *V. officinalis* L. TO IMPROVE SLEEP STRUCTURE AND ARCHITECTURE

[0168] A Phase 2, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study was performed comparing three doses of pharmaceutically-effective composition prepared from the extract, as in one or more of the above-examples, in patients with a history of insomnia for at least one month. Sixty-three (63) patients completed the study. Randomized patients took a placebo, or the pharmaceutically-effective composition prepared from the extract, as in the above-examples, at doses of 250, 500, or 1000 mg per day. Study medication was provided as identically appearing film-coated (smell and taste masked) tablets containing either placebo or 250 mg of the pharmaceutically-effective composition prepared from the extract. After an eight (8)-night placebo lead-in period and a baseline PSG study, medication was taken prior to bedtime on nine (9) consecutive nights. A three (3)-night placebo lead out phase followed. There were eight (8) visits to the sleep center after screening, on Day-8 for accommodation; Days-7 and -6 for baseline PSG; Day 1 for randomization and PSG; Days 2, 8, and 9 for PSGs; and Day 13 for follow up.

[0169] This study indicated that the pharmaceutically-effective composition prepared from the extract directly, and beneficially affected sleep maintenance. For example, the PSG variable, Wake After Sleep Onset, the most direct PSG indicator of sleep maintenance, showed a statistically significant dose effect and difference from the placebo for

the pharmaceutically-effective composition prepared from the extract. A responder analysis, based upon a responder definition emphasizing sleep maintenance, clearly demonstrated a dose response with the pharmaceutically-effective composition prepared from the extract. Beneficial effects on sleep architecture and quality were also observed in association with improvements in sleep maintenance.

EXAMPLE 20

USE OF AN EXTRACT OF THE ROOT OF THE PLANT *V. officinalis* L. TO IMPROVE
SLEEP STRUCTURE AND ARCHITECTURE

[0170] A Phase 2, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study is performed comparing eight doses in patients with a history of insomnia for at least one month. Sixty-three (63) patients completed the study. Randomized patients took a placebo, or the pharmaceutically-effective composition prepared from the extract, as in one or more of the above-examples, at doses of 100, 200, 250, 500, 1000, 2000, 3000, or 5000 mg per day. Study medication is provided as identically appearing film-coated (smell and taste masked) tablets containing either placebo or 100 mg the pharmaceutically-effective composition prepared from the extract. After a two (2)-night placebo lead-in period and baseline PSG study, medication is taken prior to bedtime on nine (9) consecutive nights. A three (3)-night placebo lead out phase followed. There are eight (8) visits to the sleep center after screening, on Day-8 for accommodation; Days-7 and -6 for baseline PSG; Day 1 for randomization and PSG; Days 2, 8, and 9 for PSGs; and Day 13 for follow up.

[0171] This study indicates that the pharmaceutically-effective composition prepared from the extract directly, and beneficially affected sleep induction and sleep latency (SL/SOL). For example, the Latency to Persistent Sleep (LPS) parameter, and related data show a statistically significant dose effect and difference from the placebo for the pharmaceutically-effective composition prepared from the extract. A responder analysis, based upon a responder definition emphasizing sleep maintenance, clearly demonstrates a dose response with the pharmaceutically-effective composition prepared from the extract. Beneficial effects on sleep maintenance, architecture and quality are also observed in association with improvements in sleep induction and latency.

EXAMPLE 21

DOSAGE EXPERIMENT REGARDING THE USE OF AN EXTRACT OF THE ROOT OF
THE PLANT *V. officinalis* L. TO IMPROVE SLEEP STRUCTURE AND
ARCHITECTURE

[0172] The following study was conducted as a Phase 2, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study comparing three (3) doses of a pharmaceutically-active extract of Valerian as, as described herein, in patients with a history of insomnia for at least one (1) month. A history of insomnia was characterized by difficulty initiating sleep. Approximately 68 patients were to be randomized to placebo or a pharmaceutically-active extract of Valerian as described herein at doses of 250, 500, or 1000 mg/day. Study medication was provided as identically appearing film-coated (smell and taste masked) tablets containing either placebo or 250 mg of a pharmaceutically-active extract of Valerian as described herein. After an 8-night placebo lead-in period and baseline PSG, study medication was to be taken 45 minutes prior to bedtime for 9 consecutive nights. After the treatment phase, a 3-night placebo lead-out phase was implemented to assess rebound insomnia. There were 8 visits to the sleep center after screening: on Day -8 for an accommodation night; Days -7 and -6 for baseline PSGs; Day 1 for randomization and PSG; Days 2, 8, and 9 for PSGs; and Day 13 for follow-up. The main criteria for inclusion were: patients 18 to 65 years with a verbal history of insomnia for at least 1 month and difficulty initiating sleep for an average of at least 4 to 7 consecutive nights per week; PSG results consistent with mean sleep latency of at least 30 minutes but no longer than 60 minutes; sleep latency on any baseline night could not be less than 20 minutes; screening diaries describing sleep latency on average of at least 30 minutes but not greater than 90 minutes; respiratory disturbance index (apneas and hyponeas) less than or equal to 10 per hour; oxygen saturation not less than 85% overnight; and no more than 10 periodic leg movements with greater than 3-second arousals during the accommodation night.

[0173] Conditions identical to those listed in Example 20 were created, except that this protocol was amended to widen the baseline PSG sleep latency window. The lower limit of the mean sleep latency (second criteria listed above) was decreased to 20 minutes and the lower limit of the sleep latency on any given baseline night (third criteria listed above) was decreased to 15 minutes.

[0174] The selected criteria for exclusion in this example were: transient insomnia, situational insomnia, insomnia associated with changes in sleep-wake schedules, or insomnia associated with the use of drugs or alcohol; illness-induced insomnia; history of chronic obstructive pulmonary disease; history of routine or habitual daytime napping; history or presence of seizure disorders or history of more than a single childhood febrile seizure; history of clinically significant head trauma; history of thyroid disease or abnormal thyroid function not clinically stable for at least 1 year with documented normal serum T4 within 6 months of study entry; history or current diagnosis of major psychiatric disorders, schizoaffective disorders, mania, and major depression that was likely to affect the study; recent history of illicit drug use or excessive daily caffeine or alcohol consumption, or alcohol abuse.

EXAMPLE 22

SELECTION OF EXAMPLES OF CRITERIA USED FOR EVALUATION

[0175] One of the primary efficacy endpoint analyzed was the change in sleep latency as measured by the PSG from baseline to "early" efficacy evaluation nights (the mean of Days 1 and 2) and from baseline to "late" efficacy evaluation nights (the mean of Days 8 and 9). Secondary efficacy endpoints were also analyzed; these included the change (typically expressed as a percentage change) from baseline in one or more of the following PSG parameters: latency to persistent sleep; wake after sleep onset; total sleep time; sleep efficiency; time in Stages 1, 2, 3-4, and REM; REM latency; number of awakenings; movement time; and number of stage shifts. Microarousal, quantified by cyclic alternating pattern (CAP) scoring, was added as a secondary variable in this study. This CAP scoring was done at 2 study centers (Center for Research in Sleep Disorders, Dr Scharf's site, and Scharf Institute for Sleep Research, Dr Kallay's site) prior to the unblinding of the study.

[0176] Additional secondary efficacy endpoints included, but need not have been limited to, change from baseline in patient diary scores of subjective sleep latency, sleep duration, number of awakenings, number of minutes awake, sleep quality, mood, alertness, number of naps, Pittsburgh Sleep Quality Index (PSQI), and the Beck Anxiety Inventory.

[0177] Safety measurements included the occurrence of specific adverse events, recognized by those of skill in the art, as well as common, field-recognized clinical laboratory

tests, physical examinations, including assessment of electrocardiograms (EKGs), measurement of vital signs, and cognitive, psychomotor and neurological assessments taken at acceptable intervals. (Table A)

57

[0178] Table A. Study Schedule and Procedures

5/05/70

	Prescreening Day -21 to -14	Screening Day -14 to -9	Visit 1 Day -8	Visit 2 Day -7	Visit 3 Day -6	Days -5 to -1	Visit 4 Day 1	Visit 5 Day 2	Days 3 to 7	Visit 6 Day 8	Visit 7 Day 9	Days 10 to 12	Visit 8 Day 13
Informed consent	X												
Sleep diaries	X	X	X	X	X		X	X	X	X	X	X	
Pittsburgh Sleep Quality Index		X											X
Sleep diary review		X	X	X	X								
Clinical labs		X											X
Urine assessment		X											X
β -HCG	X												
Medical history	X												
Physical exam	X												
Vital signs	X	X	X	X	X		X	X	X	X	X	X	
ECG		X											
Hamilton	X												
Depression Inv ^a	X												
Beck Anxiety Inv ^a	X												
Placebo		X	X	X	X								X
PSG		X	X	X	X								X
Neurological assessment		X	X	X	X								X
Cognitive/ psychomotor test		X	X	X	X								X
Study drug							X	X	X	X	X		

EXAMPLE 23

STATISTICAL METHODS

[0179] PSG data obtained in the studies described here were averaged for each patient to yield a single variable for each time period (defined as, for example, baseline, Days 1/2 and/or Days 8/9). The mean average of the two PSGs completed after the accommodation night (on Days -7 and -6) was treated as the baseline PSG score. In a similar manner, the average of Days 1 and 2 and of 8 and 9 were considered, for purposes of these studies, the "early" and "late" PSG efficacy evaluation nights, respectively. The statistical method used for each analysis is identified on each table. All statistical testing was performed at the 2-sided 0.05 significance level.

[0180] Seventy (70) patients were involved in this study. The patients were randomized, 17 or 18 to each treatment, and 63 of the 70 patients (90%) completed the study. Each study center randomized between 4 and 22 patients. Seven patients discontinued the study prematurely, 3 patients because they wished to discontinue and 1 patient each for an adverse event, noncompliance, loss of follow-up, or other reasons.

[0181] All 70 patients received at least 1 dose of the study drug (comprising the safety population), 69 patients completed the first on-treatment PSG night (the intent-to-treat [ITT] population), and 59 patients completed the study according to protocol (the efficacy evaluable population).

[0182] There were no significant differences among groups in demographics. The mean age was between 36.8 and 45.4 years in each group (range 19 to 59 years). Overall, 50 patients (72%) were female and 19 (28%) male and 60 (87%) were Caucasian. The duration of insomnia was < 1 year for 5 patients (7%), 1-4 years for 18 patients (26%), 4-10 years for 24 patients (35%), and > 10 years for 22 patients (32%). There was a trend for placebo patients to be older (mean age 45.4 years) with a longer duration of insomnia (> 10 years for 56%).

[0183] Efficacy results suggest that, under the conditions of this study, a pharmaceutically-active extract of Valerian as described herein may improve sleep efficiency and maintenance without having a significant effect on latency.

EXAMPLE 24

SLEEP CRITERIA

[0184] Sleep latency, one of the primary efficacy variables, was significantly reduced from baseline in all treatment groups in the ITT population at Days 1/2 and Days 8/9 (with the exception of change from baseline to Days 8/9 for patients treated with 500 mg of a pharmaceutically-active extract of Valerian as described herein), with the mean decrease from baseline ranging from 11 to 18 minutes. Differences among the groups were not statistically significant. Results were similar for the efficacy evaluable population and for the variable latency to persistent sleep in the ITT population.

[0185] For the other efficacy variables, herein referred to as "secondary efficacy variables" for purposes of convenience but not as to indicate the necessary relevance of any particular efficacy variable, the effects of a pharmaceutically-active extract of Valerian as described herein were generally greater at Days 8/9 than at Days 1/2. For this reason, the text and in-text tables focus on the results at Days 8/9 while the attached tables provide data at both time points.

[0186] For the variable wake after sleep onset, the difference across all treatment groups was statistically significant at Days 8/9 ($p = 0.023$ by Kruskal Wallis Test). Wake after sleep onset for patients treated with 500 mg a pharmaceutically-active extract of Valerian as described herein was significantly less than for patients treated with placebo ($p = 0.015$) at Days 8/9. There was observed a statistically significant mean decrease ($p = 0.037$) from baseline to Days 8/9 of 12.4 minutes for patients treated with 500 mg of a pharmaceutically-active extract of Valerian as described herein compared with a smaller decrease of 6.7 minutes for patients treated with 1000 mg of a pharmaceutically-active extract of Valerian as described herein and small mean increases for patients treated with placebo or 250 mg of a pharmaceutically-active extract of Valerian as described herein (Figures 4-6 and Table B). The median values increased by 13.6 and 1.0 minutes for patients treated with placebo and 250 mg of a pharmaceutically-active extract of Valerian as described herein, respectively, and decreased by 9.3 and 13.5 minutes for patients treated with 500 mg and 1000 mg of a pharmaceutically-active extract of Valerian.

[0187] **Table B.** Change from Baseline to Days 8/9 for Selected PSSG Efficacy Variables (Intent-to-Treat Population)
For Pharmaceutically-Active Extract of Valerian As Described Herein

Variable ^a	Placebo N = 18	250 mg N = 17	500 mg N = 17	1000 mg N = 17	P-value (Method) for Treatment Effect Across All Groups (Change from Baseline to Days 8/9 ^b)
Wake After Sleep Onset (min)					
Baseline	57.6 (25.0)	43.1 (21.9)	47.9 (24.7)	52.4 (23.2)	
Days 8/9	60.5 (23.3)	46.7 (25.5)	35.5 (17.0)	45.7 (35.6)	
Change ^c	2.8 (32.2)	3.5 (19.8)	-12.4 (22.4)	-6.7 (26.9)	0.215 (F-test)
p-value ^d	0.712	0.474	0.037	0.321	0.032 (J-T)
Total Sleep Time (min)					
Baseline	382.5 (22.2)	392.9 (19.2)	390.7 (27.6)	390.5 (23.5)	
Days 8/9	394.2 (32.0)	400.4 (27.8)	414.7 (29.3)	410.5 (37.0)	
Change	11.7 (39.7)	7.5 (27.9)	24.0 (32.1)	20.0 (30.9)	0.452 (F-test)
p-value ^c	0.230	0.281	0.007	0.017	0.216 (J-T)
Sleep Efficiency—Calculated (%)					
Baseline	79.8 (4.7)	81.9 (4.2)	81.5 (5.7)	81.7 (5.2)	
Days 8/9	82.2 (6.5)	83.2 (5.8)	86.8 (6.8)	85.8 (7.7)	
Change	2.4 (8.3)	1.3 (5.7)	5.4 (6.7)	4.1 (7.1)	0.341 (F-test)
p-value ^c	0.243	0.363	0.005	0.029	0.159 (J-T)
Time in Stage 3-4 (min)					
Baseline	64.0 (29.9)	56.1 (26.2)	63.4 (28.0)	56.8 (29.0)	
Days 8/9	65.2 (32.0)	53.8 (19.2)	63.6 (29.8)	69.7 (29.5)	
Change	1.3 (23.4)	-2.4 (21.5)	0.3 (22.1)	12.9 (18.1)	0.178 (F-test)
p-value ^c	0.821	0.656	0.961	0.010	0.170 (J-T)
Number of Stage Shifts (no.)					
Baseline	79.1 (31.2)	87.8 (41.8)	84.8 (36.9)	98.4 (37.6)	
Days 8/9	78.8 (24.7)	86.3 (35.3)	81.5 (41.0)	85.2 (33.1)	
Change	-0.3 (15.1)	-1.5 (16.0)	-3.3 (31.1)	-13.2 (17.9)	0.265 (F-test)
p-value ^c	0.932	0.704	0.669	0.008	0.022 (J-T)

[0188] ^a See Section 8 for definitions of efficacy variables. Baseline, Days 8/9, and Change values are shown as mean (standard deviation).

[0189] ^b P-value for analysis of change from baseline to Days 8/9 across treatment groups. J-T = Jonckheere-Terpstra.

[0190] ^c P-value for analysis of change from baseline to Days 8/9 within each treatment group.

[0191] This study also utilized entry criteria that were based, at least in part, upon sleep latency and excluded patients with very high or low sleep latency values at screening. Exploratory analyses were performed that excluded patients with very high or low baseline values for sleep maintenance endpoints. In one such analysis, data were classified into quartiles based upon the baseline wake after sleep onset values and patients in the highest quartile were excluded (Table C). In that analysis, a pharmaceutically-active extract of Valerian as described herein showed a dose-response. For the change from baseline to Days 8/9, a pharmaceutically-active extract of Valerian as described herein treatment at doses of 500 mg and 1000 mg resulted in statistically significant ($p = 0.002$ and $p = 0.025$ by t-Test, respectively) decreases compared with placebo. In this subset of patients, total sleep time and sleep efficiency showed statistically significant improvements compared with placebo from baseline to Days 8/9 at a pharmaceutically-active extract of Valerian as described herein doses of 500 mg and 1000 mg (Table C).

[0192] **Table C.** Change from Baseline to Days 8/9 for Selected PSG Efficacy Variables [Subgroup Analysis of Intent-to-Treat Population by Baseline Wake After Sleep Onset (WASO) Subgroups, Quartiles 1, 2 and 3 (Baseline WASO ≤ 66.0)] for a Pharmaceutically-Active Extract of Valerian As Described Herein.

Variable ^a	Placebo N = 12	250 mg N = 14	500 mg N = 14	1000 mg N = 12	Statistical Table
Wake After Sleep Onset (min)	43.0 (12.5) Baseline	36.7 (18.0) Change from Baseline to Days 8/9	39.9 (18.7) p-value (Method) for change from baseline to Days 8/9: Placebo vs. a pharmaceutically-active extract of Valerian as described herein ^b	40.1 (14.7) -5.3 (29.5) 0.025 (t-Test) 0.006 (Wilcoxon)	Supplemental Table 15-D
Total Sleep Time (min)	393.2 (17.5) Baseline	398.9 (15.0) Change from Baseline to Days 8/9	398.8 (23.1) p-value (Method) for change from baseline to Days 8/9: Placebo vs. a pharmaceutically-active extract of Valerian as described herein ^b	401.6 (18.0) 20.8 (34.2) 0.066 (t-Test) 0.035 (Wilcoxon)	Supplemental Table 16-E
Sleep Efficiency-Calculated (%)	81.9 (3.7) Baseline	83.0 (3.1) Change from Baseline to Days 8/9	82.9 (4.9) p-value (Method) for change from baseline to Days 8/9: Placebo vs. a pharmaceutically-active extract of Valerian as described herein ^b	83.6 (3.7) 4.5 (7.0) 0.054 (t-Test) 0.028 (Wilcoxon)	Supplemental Table 17-E

[0193] ^a See Section 8 for definitions of efficacy variables. Baseline and Change values are shown as mean (standard deviation).

[0194] ^b Raw p-value < 0.05, all tests are two-tailed, no multiplicity. Wilcoxon = Wilcoxon rank-sum test.

[0195] There was a heretofore unexpected, statistically significant increase from baseline to Days 8/9 in mean total sleep time for patients treated with 500 mg ($p = 0.007$) and 1000 mg ($p = 0.017$) of a pharmaceutically-active extract of Valerian as described herein, at 24 and 20 minutes, respectively (Table B, above and Figures 7-9). Similarly, there was a statistically significant increase from baseline to Days 8/9 in mean sleep efficiency for patients treated with 500 mg ($p = 0.005$) and 1000 mg ($p = 0.029$) of a pharmaceutically-active extract of Valerian as described herein, corresponding to a change of 5.4% and 4.1%, respectively (Table B, above and Figures 10-12). For both variables, neither the change from baseline to Days 8/9 for patients treated with placebo or 250 mg of a pharmaceutically-active extract of Valerian as described herein nor the between-group differences were statistically significant.

[0196] From baseline to Days 8/9, patients treated with 1000 mg of a pharmaceutically-active extract of Valerian as described herein had a statistically significant mean increase ($p = 0.010$) of 12.9 minutes in Stage 3-4 sleep and a statistically significant mean decrease of 13.2 stage shifts ($p = 0.008$) (Table B, above).

[0197] Each individual patient was classified as either a responder or non-responder based upon the following definition of a responder. Responders must have: a decrease from baseline to Days 8/9 of at least 7.5 minutes in wake after sleep onset time AND an increase from baseline to Days 8/9 of at least 3% in sleep efficiency OR at least 15 minutes in total sleep time. The analysis of responders showed a dose response with a pharmaceutically-active extract of Valerian as described herein (Table D). Patients treated with 1000 mg a pharmaceutically-active extract of Valerian as described herein had the highest percentage of responders (64.7%); those treated with placebo had the lowest percentage of responders (27.8%). Patients treated with 250 mg or 500 mg of a pharmaceutically-active extract of Valerian as described herein had responder rates of 29.4% and 41.2%, respectively.

[0198] Table D. Responder Analysis (Intent-to-Treat Population)

10640

	Placebo	a pharmaceutically-active extract of Valerian as described herein 250 mg	a pharmaceutically-active extract of Valerian as described herein 500 mg	a pharmaceutically-active extract of Valerian as described herein 1000 mg
N Size per Group	18	17	17	17
No. of Responders	5	5	7	11
Percent Responders	27.8	29.4	41.2	64.7

p = 0.1060 (chi-square test for difference in percentage of responders among treatment groups);
 p = 0.0216 (chi-square test for dose-related trend)

[0199] Moreover, and also heretofore unexpected, no notable findings for time in Stage 1, time in Stage 2, time in Stage REM, REM latency, number of awakenings, or movement time, were observed, although a statistically significant increase in Stage 2 sleep from baseline to Days 8/9 ($p = 0.008$) in the 500 mg for a group treated with a pharmaceutically-active extract of Valerian as described herein. The duration of Stage 2 sleep in this treatment group at Days 8/9 was statistically significant compared with placebo ($p = 0.031$).

[0200] Sleep diary data were neither queried nor corrected by the patient after the data were reviewed at the site. A number of patients incorrectly entered clock times rather than sleep duration times on the diary card. No attempt was made to recalculate the sleep times. Data that were obviously in error were excluded from the analyses.

[0201] Sleep quality, mood on final awakening, and alertness on final awakening were rated on visual analog scales that ranged from very bad/tense/sleepy to very good/calm/alert, which were coded on a scale from 0 to 10 for analysis. The most relevant sleep diary data were for Days 3 to 7, reflecting nights when patients were at home.

[0202] Patients treated with 1000 mg of a pharmaceutically-active extract of Valerian as described herein had a mean increase from baseline to Days 3 to 7 in sleep quality of 0.4 grade; however this did not reach statistical significance; Table E, below).

[0203] There was also a significant difference among treatment groups ($p=0.004$) at baseline for the mood on final awakening evaluation, with notably higher values in the placebo group (7.4) vs. 5.3 – 5.9 for the a pharmaceutically-active extract of Valerian as described herein treatment groups. Patients treated with 500 mg of a pharmaceutically-active extract of Valerian as described herein had a statistically significant mean increase from baseline to Days 3 to 7 in mood on final awakening of 0.6 grade ($p = 0.020$; Table E, below). Similarly, patients treated with 500 mg of a pharmaceutically-active extract of Valerian as described herein had a statistically significant mean increase from baseline to Days 3 to 7 in alertness on final awakening of 0.6 grade ($p = 0.039$; Table E, below).

[0204] **Table E.** Change from Baseline to Days 3 to 7 for Selected Sleep Diary Parameters (Intent-to-Treat Population)

[0204] **Table E.** Change from Baseline to Days 3 to 7 for Selected Sleep Diary Parameters (Intent-to-Treat Population)

Variable ^a	Placebo N = 17	a pharmaceutically- active extract of Valerian as described herein 250 mg ^b	a pharmaceutically- active extract of Valerian as described herein 500 mg N = 17	a pharmaceutically- active extract of Valerian as described herein 1000 mg N = 17	P-value (Method) for Treatment Effect Across All Groups (Days 3 to 7)
Sleep Quality					
Baseline ^d	6.4 (1.6)	5.2 (1.9)	5.9 (1.5)	5.2 (2.0)	
Days 3 to 7	6.3 (1.6)	5.4 (1.4)	6.1 (1.4)	5.6 (2.1)	0.650 (ANCOVA)
Change	0.1 (0.8)	0.0 (0.9)	0.2 (0.8)	0.4 (1.0)	0.517 (KW)
p-value ^e	0.709	0.967	0.414	0.162	
Mood on Final Awakening					
Baseline ^d	7.4 (1.6)	5.4 (2.0)	5.9 (1.6)	5.3 (1.9)	
Days 3 to 7	7.3 (1.7)	5.7 (1.6)	6.5 (1.6)	5.5 (1.8)	0.327 (ANCOVA)
Change	0.1 (1.0)	0.1 (0.9)	0.6 (0.9)	0.2 (1.0)	0.023 (KW)
p-value ^e	0.681	0.729	0.020	0.333	
Alertness on Final Awakening					
Baseline ^d	6.5 (2.1)	5.2 (2.1)	5.3 (1.8)	4.8 (2.1)	
Days 3 to 7	6.6 (1.9)	5.5 (1.9)	5.8 (1.7)	5.0 (2.1)	0.457 (ANCOVA)
Change	0.1 (0.8)	0.1 (1.0)	0.6 (1.0)	0.2 (1.0)	0.136 (KW)
p-value ^e	0.664	0.759	0.039	0.397	

^a Scored on a visual analog scale and coded from 0 (very bad/tense/sleepy) to 10 (very good/calm/alert). Baseline, Days 3 to 7, and

Change values are shown as mean (standard deviation).

[0206] ^b N at baseline = 17. N at Days 3 – 7 = 16. Change value based on 16 patients.

[0207] ^c P-value for analysis of Days 3-7 results across treatment groups. ANCOVA = analysis of covariance, KW=Kruskal-Wallis.

[0208] ^d Baseline defined as the average of non-PSG days –5 to –1, during the placebo lead-in.

[0209] ^e P-value for analysis of change from baseline to Days 3-7 within each treatment group.

[0210] No statistically significant changes compared with placebo were noted for the subjective evaluations of sleep latency, sleep duration, or number of awakenings. There were no significant changes from baseline to treatment Days 3-7 (at home nights). Although statistically significant changes from baseline to Days 1/2 (PSG nights) were seen for the a pharmaceutically-active extract of Valerian as described herein, 1000 mg treatment group for subjective sleep latency and sleep duration, similar changes were also seen in the placebo group. Statistically significant increases from baseline to Days 1/2 in subjective evaluations of number of awakenings were observed in all treatment groups except a pharmaceutically-active extract of Valerian at 1000 mg. No serious adverse events were reported during the study. Patient 515, who received 1000 mg of a pharmaceutically-active extract of Valerian as described herein, experienced a severe migraine (considered possibly related to study medication) on Day 10, the first day of the placebo lead-out phase, and withdrew from the study because of this adverse event.

[0211] During randomized study drug administration and the placebo-lead out period, one or more adverse events were reported for 10 patients (56%) treated with placebo, 9 (53%) treated with 250 mg of a pharmaceutically-active extract of Valerian as described herein, 6 (33%) treated with 500 mg, and 8 (47%) treated with 1000 mg. Headache was the most frequent adverse event, reported for 16 patients (23%) overall, including 3 to 5 patients (18% to 29%) in each treatment group. Adverse events reported for more than 1 patient overall were upper respiratory tract infection and back pain (each 3 patients, 4%), and dyspepsia, sore throat, and abnormal gait (each 2 patients, 3%).

[0212] Adverse events considered probably related to study drug were lethargy and limb pain (each 1 patient treated with 250 mg of a pharmaceutically-active extract of Valerian. Adverse events considered possibly related (each 1 patient except where noted otherwise) in the placebo group were headache (2 patients), dyspepsia, fatigue, increased lymphocyte count, decreased neutrophil count, increased RBC, decreased WBC, back pain, dysmenorrhea, and nasal congestion. Possibly related events with a pharmaceutically-active extract of Valerian as described herein treatment were headache (4 patients) and road traffic accident in the 250 mg group; headache (2 patients) and upper respiratory tract infection in the 500 mg group; and headache (3 patients), migraine, and abnormal gait in the 1000 mg

group. Adverse events were usually mild or moderate in intensity. The only severe event that was considered possibly related to study drug was migraine in 1 patient in the 1000 mg group.

[0213] During the placebo-lead in period, one or more adverse events were reported for 7 patients (39%) subsequently randomized to placebo, 6 (35%) to 250 mg a pharmaceutically-active extract of Valerian as described herein, 8 (44%) to 500 mg, and 4 (24%) to 1000 mg. Headache was the most frequent adverse event, reported for 10 patients (14%) overall, including 2 or 3 patients (11% to 18%) in each treatment group. Adverse events reported for more than 1 patient overall were constipation, nausea, and sore throat (each 3 patients, 4%), and upper abdominal pain (2 patients, 3%).

[0214] No statistically or clinically significant changes from baseline were observed for the laboratory parameters. These results suggest that, unlike currently available hypnotic products, a pharmaceutically-active extract of Valerian as described herein appears to affect sleep maintenance rather than sleep initiation. The PSG variable wake after sleep onset, the most direct PSG indicator of sleep maintenance, showed a statistically significant dose effect for a pharmaceutically-active extract of Valerian as described herein. This variable was decreased from baseline by 7 to 12 minutes at a pharmaceutically-active extract of Valerian as described herein doses of 500 or 1000 mg for Days 8/9. In addition, a responder analysis based upon a responder definition emphasizing sleep maintenance clearly demonstrated a dose response with a pharmaceutically-active extract of Valerian as described herein. Exploratory analyses indicate that entry criteria based upon sleep maintenance endpoints could identify a group of patients likely to show efficacy with a pharmaceutically-active extract of Valerian as described herein in a future trial.

[0215] Theoretically, the variables sleep efficiency and total sleep time may be improved by a decrease in sleep latency and/or a decrease in wake after sleep onset. Despite the lack of effect upon sleep latency by a pharmaceutically-active extract of Valerian as described herein, a pharmaceutically-active extract of Valerian as described herein treatment at doses of 500 or 1000 mg for Days 8/9 was associated with an increase from baseline in total sleep time of 20 to 24 minutes and an increase from baseline in sleep efficiency of 4% to 5%.

[0216] Associated with this improvement in sleep maintenance is a demonstration of some relevant effects upon sleep architecture and sleep quality. At the 1000 mg dose of a pharmaceutically-active extract of Valerian as described herein for Days 8/9, an increase from baseline of 13 minutes in slow wave (Stage 3-4) sleep and a 13% reduction from baseline in sleep stage shifts were observed. Subjective diary assessments on Days 3 to 7 showed improvement in mood and alertness on final awakening at 500 mg of a pharmaceutically-active extract of Valerian as described herein compared with baseline; improvement from baseline in sleep quality approached statistical significance at 1000 mg of a pharmaceutically-active extract of Valerian as described herein.

[0217] The following observations support a pharmacologic effect of a pharmaceutically-active extract of Valerian as described herein. Firstly, a consistent dose response pattern was noted across variables; all of the statistically significant effects at Days 8/9 were found with either 500 or 1000 mg of a pharmaceutically-active extract of Valerian as described herein, while there were no significant effects with 250 mg of a pharmaceutically-active extract of Valerian as described herein. Secondly, with 500 and 1000 mg of a pharmaceutically-active extract of Valerian as described herein more prominent effects were seen at the "late" PSG efficacy evaluations rather than the "early" efficacy evaluations. In contrast, recently approved hypnotics such as Sonata[®] (zaleplon) and Ambien[®] (zolpidem) have demonstrated effects more consistently at early time points rather than late time points in PSG and/or subjective endpoint clinical trials.

[0218] The pattern of responses seen in this study suggests that a pharmaceutically-active extract of Valerian as described herein may have particular utility in the elderly, for whom sleep maintenance is more problematic than sleep induction and who experience a naturally occurring decrease in slow wave sleep.

[0219] No serious adverse events were observed in this trial. The frequency and severity of adverse events in the a pharmaceutically-active extract of Valerian as described herein treatment groups were similar to the placebo treatment group. No clinically or statistically significant changes from baseline were observed for laboratory safety parameters.

[0220] Rather than showing an effect on sleep initiation (sleep latency), these data suggest, among other results, that a pharmaceutically-active extract of Valerian as described

herein exhibits a heretofore unexpected effect upon sleep maintenance. Changes in sleep architecture (an increase in the duration of slow wave sleep and a decrease in the number of sleep stage shifts) is consistent with this result, and as an improvement in sleep quality. Moreover, the safety profile of a pharmaceutically-active extract of Valerian as described herein is similar to that of placebo.

[0221] The various articles of the scientific and/or medical literature, and the U.S. and international and/or foreign patents and patent applications cited herein are hereby incorporated by reference to the extent permitted by law. To the extent that each is incorporated by reference herein, each constitutes a part of the disclosure of this specification. Furthermore, specific embodiments, working examples, and prophetic examples of the invention have been described in detail to illustrate the broad applicability and principles underlying the invention. Notwithstanding these specific embodiments, working examples, and prophetic examples, it will be understood by those of skill in the art that the invention may be embodied otherwise without departing from such broad applicability and principles.